Clarifying Values: An Updated and Expanded Systematic Review and Meta-Analysis

Holly O. Witteman[1,2,3], Ruth Ndjaboue[1,2,] Gratianne Vaisson[1], Selma Chipenda Dansokho[1], Bob Arnold[4], John F. P. Bridges[5], Sandrine Comeau[1], Angela Fagerlin[6], Teresa Gavaruzzi[7], Melina Marcoux[1], Arwen Pieterse[8], Michael Pignone[9], Thierry Provencher[1], Charles Racine[1], Dean Regier[10], Charlotte Rochefort-Brihay[1], Praveen Thokala[11], Marieke Weernink[12], Douglas B. White[13], Celia E. Wills[14], Jesse Jansen[15]

[1]Department of Family and Emergency Medicine, Faculty of Medicine, Laval University, Quebec City, Canada
[2]VITAM Research Centre, Quebec City, Canada
[3]CHU de Québec Research Centre, Quebec City, Canada
[4]UPMC Palliative and Supportive Institute; University of Pittsburgh, Division of General Internal Medicine, Section of Palliative care and Medical ethics, Pittsburgh, PA, USA
[5]Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA
[6]Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA
[7]Department of Developmental Psychology and Socialization, University of Padova, Padova, Italy
[8]Leiden University Medical Center, Leiden, The Netherlands
[9]Departments of Internal Medicine and Population Health, Dell Medical School, University of Texas, Austin, TX, USA
[10]School of Population and Public Health, Univ. of British Columbia, Vancouver, BC, Canada
[11]School of Health and Related Research, University of Sheffield, Sheffield, UK
[12]Municipal Health Services (GGD), Enschede, The Netherlands.
[13]Program on Ethics and Decision Making in Critical Illness, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
[14]College of Nursing, Center on Healthy Aging, Self-Management and Complex Care, Ohio State University, Columbus, OH, USA
[15]Department of Family Medicine/CAPHRI, Maastricht University, Maastricht, The Netherlands

Corresponding author: Holly O. Witteman, 1050 avenue de la Médecine, Pavillon Ferdinand-Vandry, Université Laval, Québec City, Québec, G1V 0A6, Canada, telephone: 418.656.2131 x3981, fax: 418-656.2465, email: holly.witteman@fmed.ulaval.ca

Abstract

Background: Patient decision aids should help people make evidence-informed decisions aligned with their values. There is limited guidance about how to achieve such alignment.

Purpose: To describe the range of values clarification methods available to patient decision aid developers, synthesize evidence regarding their relative merits, and foster collection of evidence by offering researchers a proposed set of outcomes to report when evaluating the effects of values clarification methods.

Data Sources: MEDLINE, EMBASE, PubMed, Web of Science, the Cochrane Library, CINAHL

Study Selection: We included articles that described randomized trials of one or more explicit values clarification methods. From 30,648 records screened, we identified 33 articles describing trials of 43 values clarification methods.

Data Extraction: Two independent reviewers extracted details about each values clarification method and its evaluation.

Data Synthesis: Compared to control conditions or to implicit values clarification methods, explicit values clarification methods decreased the frequency of values-disgruent choices (risk difference -0.04 95% CI [-0.06 to -0.02], p<.001) and decisional regret (standardized mean difference -0.20 95% CI [-0.29 to -0.11], p<0.001). Multicriteria decision analysis led to more values-congruent decisions than other values clarification methods (Chi-squared(2)=9.25, p=.01). There were no differences between different values clarification methods regarding decisional conflict (Chi-squared(2)=6.08, p=.05).

Limitations: Some meta-analyses had high heterogeneity. We grouped values clarification methods into broad categories.

Conclusions: Current evidence suggests patient decision aids should include an explicit values clarification method. Developers may wish to specifically consider multicriteria decision analysis. Future evaluations of values clarification methods should report their effects on decisional conflict, decisions made, values congruence, and decisional regret.

Introduction

Shared decision making aims to foster health-related decisions that are both informed by the best available evidence and aligned with what matters to the person or people affected by the decision. [1–4] Individual values are a critical ingredient in high quality individual health decision making. [5–7] What is important to one person might be different from what is important to others, and determining what is important to oneself can be difficult even if one has the appropriate information and evidence at hand. Therefore, patient decision aids should both present evidence appropriately and also support the process of clarifying and expressing patients' (and, when appropriate, other relevant stakeholders') values, with the goal of supporting alignment between values and decisions. Within patient decision aids, such support is offered by explicit values clarification methods.

Explicit values clarification methods require users to interact with something such as a worksheet or an interactive website to clarify what matters to them relevant to a health decision. Such methods have been shown to encourage desirable outcomes such as better alignment with patients' values [8, 9] and reduced decisional regret, the latter particularly among people with lower health literacy. [10] However, explicit values clarification methods are extremely diverse, [11], and there has been little guidance regarding their comparative effects on users' decision-making processes or outcomes [12], making it difficult for patient decision aid developers to know which explicit method to use. Patient decision aid developers might look towards the preference elicitation literature for guidance, but the guidance available [13] is often tailored towards aggregate level decision making, such as regulatory decisions [14] or health technology assessment [15], not for supporting individual-level decision making.

This updated review sought to build upon previous versions of the International Patient Decision Aids Standards' Chapter on Values Clarification [16, 17] as well as previous evidence syntheses that have established the advantages of explicit values clarification methods over implicit methods or no values clarification. [8, 9] We sought to advance the science and practice of values clarification methods in three ways. First, we aimed to offer clear definitions and an annotated summary of existing approaches that have been or could be used as values clarification methods. Second, we aimed to synthesize evidence of different techniques' effects on health decision outcomes. Third, we aimed to foster future evidence by offering researchers a proposed set of outcomes to consider when evaluating the effects of values clarification methods.

Definitions

Part of the challenge in studying or using values clarification methods is that definitions vary and terms like 'values' are used imprecisely in the patient decision support literature. [18, 19] Another challenge is that there is substantial overlap between values clarification methods used in patient decision support and preference elicitation methods used in health economics. To bring clarity to this imprecision and overlap, we adopt working definitions in Table 1 for use in this paper.

Table 1. Definitions of Terms

Term	Definition adopted in this paper
Values	An umbrella term referring to what matters to an individual relevant to a health decision. Values may be directly relevant to decisions (e.g., "beliefs, feelings, or perceptions regarding attributes of a treatment option") or indirectly relevant (e.g., goals; worldviews; family, religious, or cultural values). [20] Values may be represented qualitatively or, in some cases, quantitatively. This definition is

	deliberately broad.
Values clarification	"The process of sorting out what matters to an individual relevant to a given health decision." [11] This definition emphasizes that what matters to an individual may be broader than attribute-specific values. What matters may also include preferences, concerns, and issues to do with the context of a person's life within which they would need to implement a decision.
Values clarification methods	"Strategies that are intended to help patients evaluate the desirability of options or attributes of options within a specific decision context, in order to identify which option [they] prefer." [17]
Implicit values clarification methods	Strategies for facilitating values clarification that do not require people to interact with anything or anyone; e.g., describing "options in enough detail that clients can imagine what it is like to experience the physical, emotional, and social effects," [9] or simply encouraging people to think about what matters to them.
Explicit values clarification methods	Strategies for facilitating values clarification that require people to interact with something or someone; e.g., filling out a worksheet, using an interactive website, having a semi-structured conversation with another person with the explicit purpose of clarifying values, or engaging in another structured exercise.
Preferences	The extent to which a decision option or health state is desirable or acceptable, either in the abstract or in comparison to other options or health states. Preferences may be represented qualitatively or, more commonly, quantitatively. [21]
Preference elicitation methods	Processes by which preferences are drawn out. [11] Preference elicitation methods may vary according to the theory informing them. They are highly related to values clarification methods. Although older terms "revealed" and "stated" preference elicitation methods are no longer recommended, readers who encounter these terms in previous preference elicitation literature should note that these may overlap with implicit and explicit values clarification methods, respectively.

As noted above, we continue to use the term values clarification even though this is sometimes misinterpreted as implying a narrow definition of values. Changing terms makes it difficult for people who are new to a field to connect the dots across decades of previous research. It is clear that previous research in values clarification addressed issues that were broader than valuation of treatment-specific attributes. [16] In this update, we therefore move forward with the older terms, now with more clarity about what they mean in our presentation of the evidence.

Theoretical Rationale

Our interdisciplinary team determined that the theoretical rationale for values clarification required only a small edit, shown in square brackets, to reflect the focus on explicit methods. Like Fagerlin and colleagues, we assert the theoretical rationale for explicit values clarification methods as being that they, "should aim to [explicitly] facilitate at least one or more of the following six decision-making processes: 1) Identifying options, which can include either the narrowing down of options, or the generation of options that were not offered at the outset, 2) Identifying attributes of the situation and/or the options which ultimately affect the patient's preference in a specific decision context, 3) Reasoning about options or attributes of options, 4) Integrating attributes of options using either compensatory or both compensatory and non-compensatory decision rules, 5) Making holistic comparisons, and 6) Helping decision makers retrieve relevant values from long-term memory." [17] Pieterse and colleagues provided theory-based recommendations on processes that values clarification methods could aim to facilitate. [22]

Although reasoning is one of the potential processes supported by values clarification, neither the definition nor the theoretical rationale of values clarification methods requires that people who are being supported in making a personal health decision must rationally deliberate about each option, nor that the goal must always be a fully rational choice. In some decision-making situations, rational deliberation and rational choice may be desired, while in others, they may not. [23, 24]

Explicit Values Clarification Methods

Table 2 organizes strategies that can be used as explicit values clarification methods in patient decision aids, building upon previously-developed lists of types of values clarification methods [7, 11] and reviews of preference elicitation methods. [25, 26] Methods range from highly structured strategies that can also be used for preference elicitation in the context of health policy decision making to substantially less structured strategies. While not every use of a given method will be exactly the same, we deemed them functionally similar in terms of how they might be used and what the user experience might be in a patient decision aid. Patient decision aids may use multiple strategies. For example, a user may be asked to use a rating scale or visual analog scale whose values are then used in a decision analytic model.

Table 2. Values Clarification Methods

Method	**Description**
Adaptive Conjoint Analysis (example [27])	The user rates a series of sets of attributes and their levels, where choices presented are tailored to earlier answers.
Allocation of Points (example [28])	The user has a “budget” to “spend” on decision attributes, according to their importance.
Analytical Hierarchy Process (example [29])	The user is asked to compare sets of options relative to predefined decision criteria.
Best-Worst Scaling (example [30])	The user is asked to indicate the best and the worst in sets of options with different attributes and levels.
Decision Analysis or Multicriteria Decision Analysis (umbrella term*) (resource [31, 32])	The user is asked to directly indicate the extent to which a decision attribute or outcome matters to them or how good or bad they deem it to be. These values are then used in a model that calculates alignment between what matters to the user and the available decision options.
Discrete Choice Experiments (example [33])	The user is asked to make a series of choices between two (or more) alternatives, where each alternative is characterized by attributes and their associated levels.
Open Discussion (example [34])	The user makes a list and/or discusses what matters to them in an unstructured or semi-structured discussion.
Pros and Cons (resource [35])	The user lists advantages (pros) and disadvantages (cons) of options and/or indicates the relevance (‘this matters to me’) or importance (e.g., on a Likert scale) of each advantage or disadvantage
Ranking (example [36])	The user is asked to place attributes in order of importance, relative to each other.
Rating Scales (example [37])	The user indicates the importance of an attribute on a visual analog scale (e.g., paper-based visual analog scale, online slider) or Likert scale approximating a visual analog scale. If the rating is then used to calculate and show which option fits best, the method is classified as (multicriteria) decision analysis.

Social Matching (example [38])	The user “observes different characters’ decisions and/or decision-making processes and identifies 1 or more characters” with whom they identify. [11]
Standard Gamble (example [39])	The user indicates their willingness to accept a certain risk of death in order to avoid a particular health state by choosing between the certainty of living in that health state for the remainder of their life versus a gamble between two possible outcomes: life in a state of optimal health, with probability p, or immediate death, with probability (1−p).
Time Tradeoff (example [39])	The user indicates how many years in their current health state they would be willing to 'trade off', in order to regain full health.

*Multicriteria decision analysis or decision analysis is an umbrella term. It encompasses some of the other, more specific categories (e.g., discrete choice experiments, best-worst scaling.) When applicable, we use the more specific, narrower categories. Otherwise, we use the umbrella term “multicriteria decision analysis,” or, for brevity in figures, “decision analysis.” Additionally, although within multicriteria decision analysis, the user may be asked to rate attributes on rating scales, what distinguishes multicriteria decision analysis from other methods such as rating scales is that the model calculates how well or poorly the options align with what matters to a user.

Methods

Our overall methods were guided by the Cochrane Handbook. We report according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [40] guidelines.

Eligibility criteria

We included published reports of comparative evaluations of explicit values clarification methods, whether they were called ‘values clarification methods’ in the publications or not. This meant that we included trials of preference elicitation methods that had been trialed as values clarification methods; for example, multi-criteria decision analysis or discrete choice experiments. We included evaluations using comparative methods; i.e., randomized controlled trials or randomized experiments of one or more values clarification methods. The comparisons could be one or more values clarification methods compared to a control method, or compared to each other. Because we sought to understand the effects of values clarification methods, we excluded evaluations using descriptive study designs (e.g., acceptability and feasibility study, development study), observational study designs (e.g., reporting outcomes before and after use of a values clarification method), and reports of values clarification methods that did not evaluate the method independently of the patient decision aid in which it was used. Randomized experiments comparing one or more values clarification methods had to use distinctly different methods, meaning that more than the content or presentation of information in the values clarification method varied.

We did not apply language restrictions. We applied date restrictions to the portion of the review for which we had already conducted a systematic review (i.e., evaluations of values clarification methods that used the term ‘values clarification’. [12, 17] Specifically, for this subgroup, we added articles indexed or published starting in 2014 to the existing set of articles indexed or published prior to 2014 that we had already identified using the same search strategy. We applied no date restrictions to the new, expanded portion of the review (i.e., evaluations of values clarification methods that did not use the term ‘values clarification’).

Information sources

We performed a systematic literature search in MEDLINE, EMBASE, Web of Science, the Cochrane Library, and CINAHL.

Search strategy

We developed a draft search strategy in collaboration with an information specialist (FB, see Acknowledgments). Search strategies for each database are shown in Online Appendix 1. We reviewed search strategies with all authors to ensure they were inclusive of relevant preference elicitation methods that might be used for values clarification. We conducted hand searches by reviewing articles that cited the previous version of these standards (values clarification chapter) or a previous systematic review of values clarification methods.

Study records: Data management

We managed data with Covidence (covidence.org, Melbourne, Australia), reviewing data records at regular team meetings.

Study records: Selection process

Two independent reviewers (SC, MM, TP, CR, CRB) screened titles and abstracts to assess potential relevance, with a third reviewer adjudicating discrepancies and discussions of questions and points of disagreement at regular team meetings. Two independent reviewers then reviewed the full text of all articles deemed potentially relevant based on their title and abstract. Discrepancies in inclusion and exclusion at full text were adjudicated through team discussions at regular meetings until we reached consensus.

Study records: Data collection process

Two independent, trained research team members (SC, MM, TP, CR, CRB) extracted data from each article using a standardized and pilot-tested data extraction form based on a previous form [12] and adapted to this review. We resolved lack of agreement through discussion until consensus was reached. We contacted authors to collect any needed data that they did not report or were unable to report in their publication.

Data items

Regarding study participants, we recorded the sample size for control and intervention groups along with basic inclusion and exclusion criteria and whether or not they were making the actual decision or if the study was hypothetical. We defined a hypothetical scenario as one in which people are asked (explicitly or implicitly) to imagine that they are in a certain situation or facing a certain decision. We defined a real scenario as one in which people are facing a decision (e.g., because they have received a diagnosis) or are members of a population likely to face the decision in the near term (e.g., parents of children eligible to receive vaccines within the coming months.)

Regarding interventions, we recorded the type of explicit values clarification method as listed in Table 2. We also recorded specific characteristics of each values clarification method, namely, whether it explicitly requires the user to engage with tradeoffs (i.e., considering which potential harms are acceptable in exchange for their associated potential benefits), whether it explicitly shows the user the correspondence between their options and what they value, and which, if any, theoretical or conceptual framework underpins it. Where relevant, we recorded whether a variable was collected via self-report, meaning whether responses were completed by participants themselves, or by independent researchers based on direct observation, including coded qualitative data.

For comparators (controls) we recorded whether the comparator was no values clarification method or an implicit method, and treated both as equivalent controls. The Cochrane review of patient decision aids

specifies that all patient decision aids must contain implicit values clarification methods at minimum [9] and it is accordingly rare to have patient decision aids that do not present potential benefits and harms of options in organized ways. In other words, in the context of patient decision aids, there is no meaningful distinction between implicit methods and no values clarification. The different terminology is simply a function of how authors choose to name their control. We also recorded studies that compared different types of explicit values clarification methods to each other.

Outcomes

Whenever such data were available, we extracted data regarding values congruence as our primary outcome, as well as secondary outcomes: decision readiness (worry, decision uncertainty, decision-making preparation, knowledge); decisional conflict; decision made; post-decision and post implementation health and well-being (decisional regret, longer-term health outcomes). Following data extraction by pairs of trained reviewers (SC, MM, TP, CR, CRB), three authors (HOW, SCD, JJ) mapped all outcomes into broad outcome groups: worry (including perceived risk), decision uncertainty (not including decisional conflict), decisional conflict (decisional conflict scale or any subscales), decision-making preparation (including self-efficacy for decision-making), beliefs (including beliefs about the condition or underlying decision structure), knowledge, values (including reported utilities), shared decision making, effects on communication (including quality, length, or existence of communication), satisfaction with care, preferences, decision (choice made and implemented) or decisional intent (choice intended, or made and not yet implemented), values congruence, informed decision making, post-decision feelings (including satisfaction, regret), post-decision health, and user assessment of the intervention (including acceptability, satisfaction, perceived balance.) We conducted meta-analyses on primary outcome values congruence and secondary outcome decisional conflict, as these outcomes had sufficient studies to do so.

Risk of bias in individual studies

Independent, trained research team members assessed risk of bias for each study using methods as defined in the Cochrane Handbook, section 8.5. [41] We conducted quantitative data syntheses with and without studies identified as being at high risk of bias to determine the sensitivity of overall findings to these studies.

Data synthesis

We synthesized frequency-based results (e.g., how many values clarification methods reflect a given design) descriptively. To synthesize effects on outcomes, we pooled all experiments that evaluated a values clarification method against no values clarification method or an implicit method. For multi-armed studies in which the comparison of a decision aid with and without a values clarification method included an arm that was not relevant to our comparison of interest (for example, an information booklet serving as a control condition in an evaluation of the decision aid) we ignored the third arm. For multi-armed studies containing two or more different values clarification methods and one arm of implicit values clarification or control, we considered each comparison of a values clarification method against implicit values clarification, meaning that each of the multi-armed studies included in this review contributed multiple comparisons to the pooled set.

To meta-analyze results for values congruence, we pooled results using risk differences and applying a random effects model. We extracted dichotomous data indicating the frequency (i.e., number of events and sample size) of values discongruent decisions. To meta-analyze results for decisional conflict, we pooled results using standardized mean differences applying a random effects model. We extracted data on total scores on the Decisional Conflict Scale. We explored and reported consistency using Higgins I^2 [42]. We used the Cochrane Risk of Bias tool to assess study bias along 7 domains as well as to assess an overall risk

of bias. Where data permitted, we conducted subgroup meta-analyses of different types of explicit values clarification methods and of explicit values clarification methods that do and do not contain specific design features already identified in previous work [11], namely, whether the method explicitly requires the user to engage with tradeoffs, whether it explicitly provides the user with the implications of what they value, and which, if any, theoretical or conceptual framework underpins it. We used p=0.05 as a threshold for statistical significance and conducted analyses in RevMan, version 5.4.

Results

Articles identified

Out of 30,648 records screened at the title and abstract stage and 279 screened at the full text stage, we identified 33 articles that met our inclusion criteria describing trials of 43 values clarification methods. Twenty-four of the articles were new articles identified in this update of IPDAS. We excluded 2 of the articles previously included in the IPDAS Values Clarification Chapter because they did not meet our revised inclusion criteria requiring randomized controlled trials and instead reported, for example, pre-post study designs. The PRISMA diagram of included articles is shown in Figure 1.

Figure 1. PRISMA Diagram



The decision context varied across studies. Out of the 43 included trials, 25 (58%) addressed treatment decisions, 9 (21%) screening decisions, 4 (9%) prevention, 3 (7%) genetic testing, and 2 (5%) diagnostic testing. Thirteen of the 43 trials (30%) centered around a yes/no decision to take an option or not, 18 (42%) a choice between two or more options and 12 (28%) both a yes/no and a choice between two or more options. Most decisions (22/43, 51%) were real decisions, meaning that the person was making this decision in their actual life. The rest were hypothetical (18/43, 42%) or it was not entirely clear whether the decision was real or hypothetical (3/43, 3%). The most commonly-reported outcomes were decisional conflict and/or its subscales (29/43, 67%), decision and/or decisional intentions (22/43, 51%), knowledge (13/43, 30%), and values congruence (12/43, 28%).

As shown in the overview of included studies in Table 3, there was substantial diversity in the types of values clarification methods used. Decision analysis or multicriteria decision analysis was the most commonly trialed method. Full study details are available in Online Appendix 2.

Table 3. Study Details

Type(s) of Values Clarification Method(s)	**Study**	**Population***	**Decision**	**Summary of findings**
Adaptive Conjoint Analysis	de Achaval and others 2012 [43]	n=208 people with knee osteoarthritis	Whether to receive medication and therapy or total knee arthroplasty	Values clarification method decreased decisional conflict and required more intense cognitive involvement.
Adaptive Conjoint Analysis	Fraenkel and others 2007 [44]	n=87, age at least 60 years old, self report of pain involving one or both knees on most days of the month	Choice between five treatments for knee pain	Values clarification method increased self-confidence in and preparation for shared decision-making, and increased arthritis self-efficacy.
Adaptive Conjoint Analysis	Hess and others 2015 [45]	n=374 women aged 18 years or older with abnormal uterine bleeding & potential candidates for either surgical or medical treatment	Whether or not to be treated for abnormal uterine bleeding, and, if yes, which treatment to undertake	Values clarification method did not reduce decision regret nor improve treatment satisfaction.
Adaptive Conjoint Analysis	Hutyra and others 2019 [46]	n=200 people between 18 and 35 years of age at risk for experiencing a first-time anterior shoulder dislocation	Operative or nonoperative treatment for first-time anterior shoulder dislocation	Values clarification method increased alignment between patients' treatment decisions and evidence-based recommendations.
Adaptive Conjoint Analysis	Jayadevappa and others 2015 [47]	n=743 people with newly diagnosed localized prostate cancer	Choice between six options for early stage prostate cancer	Values clarification method improved satisfaction with care, satisfaction with decision, reduced regrets, and aligned treatment choice with risk category.
Allocation of Points	Witteman and others 2020 [48]	n=817 adults asked to imagine they had been diagnosed with colon cancer	Choice between two hypothetical surgeries for colon cancer	Values clarification method (strategy 6b in paper) increased values congruence and reduced decisional conflict.
Analytical Hierarchy Process	Myers and others 2003 [49]	n=199 men aged 50 to 69 with no personal history of prostate cancer/benign prostate hyperplasia	Whether or not to be screened for prostate cancer	Values clarification method decreased rates of prostate cancer screening. Race/ethnicity analyses showed African American men increased screening while white men decreased screening.

Analytical Hierarchy Process	Myers and others 2005 [50]	n=242 African-American men, 40-69 years of age and no history of prostate cancer	Whether or not to be screened for prostate cancer, and if yes, choice of method/extent of screening	Values clarification method increased prostate cancer screening.
Best-Worst Scaling	Shirk and others 2017 [51]	n=122 men with incident localized prostate cancer	Choice between three options for incident localized prostate cancer	Values clarification method decreased decisional conflict.
Decision Analysis**	Bekker and others 2004 [52]	n=106 pregnant women receiving a screen positive maternal serum screening result	Whether or not to have a prenatal diagnosis for Down syndrome	Values clarification method helped women make more informed prenatal diagnosis decisions.
Decision Analysis**	Clancy and others 1988 [53]	n=1280 resident and faculty physicians unvaccinated against Hepatitis B	Choice between three options to manage risk of hepatitis B	Values clarification method resulted in greater action-taking (screening or vaccination.)
Decision Analysis**	Feldman-Stewart and others 2012 [54]	n=156 people with newly diagnosed prostate cancer	Choice between more than five main options for early stage prostate cancer	Values clarification method increased preparation for decision making and decreased decision regret. Decision conflict decreased with and without values clarification method.
Decision Analysis**	Hopkin and others 2019 [55]	n=349 adults asked to imagine that they had to choose a statin	Choice between five commonly-used statins	Values clarification method reduced decisional conflict and increased levels of preparation for decision making.
Decision Analysis**	Montgomery and others 2003 [56]	n=217 adults aged 30-80 years with newly diagnosed hypertension	Whether or not to start drug therapy for hypertension	Values clarification method increased knowledge and reduced total decisional conflict by significantly reducing scores on uninformed, unclear values and unsupported subscales and somewhat reducing scores on uncertainty subscale. Values clarification method did not influence scores on decision quality subscale, nor did it change state anxiety, decision intention, nor ultimate decision.
Decision Analysis**	Montgomery and others 2007 [57]	n=742 pregnant women with one previous lower segment caesarean section	Choice of planned mode of delivery	Values clarification method reduced decisional conflict and increased frequency of having a vaginal birth.
Decision Analysis**	Witteman and others 2015 [58]	n=407 parents who make medical decisions for at least one child aged 6 months to 18 years and whose child had not yet received the flu vaccine	Whether their child would receive a vaccine against influenza this flu season	Values clarification method had no effect on values congruence. Values clarification method combined with best practices in risk communication increased intentions to vaccinate, particularly among participants who had not had their children vaccinated against influenza in the past 5 years.
Decision Analysis**	Witteman and others 2020*** [48]	n=1731 adults asked to imagine they had been diagnosed with colon cancer deciding between two treatment options	Choice between two hypothetical surgeries for colon cancer	Values clarification method (strategies 2a, 2a+2b, 6c, 6b+6c in paper) increased values congruence and reduced decisional conflict this was when measured (strategies 6c, 6b + 6c in paper).
Discrete Choice Experiment	Brenner and others 2014 [59]	n=615 people between the ages of 50 and 75 at average	Whether or not to be screened for colorectal cancer, and, if yes,	Values clarification method influenced choice of most important screening test attribute but did not affect unlabeled test

		risk for colorectal cancer	which screening test to use	preference, values clarity, nor intent to be screened.
Discrete Choice Experiment	Pignone and others 2012 [60]	n=104 adults 48-75 at average risk for colon cancer	Whether or not to be screened for colorectal cancer, and, if yes, which screening test to use	Values clarification method influenced choice of most important attribute, but did not affect values clarity, intent to be screened, or choice of unlabeled screening test.
Discrete Choice Experiment	Pignone and others 2013 [61]	n=604 men aged 50-70 at average risk of prostate cancer	Whether or not to be screened for prostate cancer	Values clarification method slightly reduced choice of dying as the most important attribute and increased unlabeled PSA-like screening option but did not influence intent to be screened.
Open Discussion	Au and others 2012 [62]	n=306 people with chronic obstructive pulmonary disease	Preferences for end-of-life care	Values clarification method helped identify what mattered to patients regarding end-of-life care and communication. Quality of communication improved.
Open Discussion	Epstein and others 2018 [63]	n=99 people with advanced gastrointestinal cancer	Choice between options for end-of-life care	Values clarification method improved communication about future medical cancer care but had no effect on decisional conflict or well-being and increased distress.
Open Discussion	Kennedy and others 2002 [64]	n=894 women with uncomplicated menorrhagia	Choice between treatment options for menorrhagia	Values clarification method resulted in minimal improvements in self-reported health status, lower use of a more invasive treatment, higher patient satisfaction, more frequent clinician perceptions of "longer than usual" consultations, and lower overall costs. Providing information alone did not affect treatment choices.
Open Discussion	Lerman and others 1997 [65]	n=700, Women aged 18-75 years who had had at least one first-degree relative with breast and/or ovarian cancer	Whether or not to provide a blood sample for BRCA1 testing in the future	Values clarification method increased the perceived importance of the limitations and risk of BRCA1 testing and decreased the perceived importance of the benefits of BRCA1 testing. No effect of values clarification method on intent to treat.
Open Discussion	Matheis-Kraft and others 1997 [66]	n=60 women over age 70 with at least one family member or friend who might act as their proxy to make decisions about life-sustaining treatment	Preferences for care in case of decisional incapacity	Values clarification method's effectiveness or lack thereof depended on which statistic (kappa or percent agreement) was used to measure concordance between women and proxies.
Pros and Cons	Abhyankar and others 2010 [67]	n=30 healthy women asked to imagine having been diagnosed with breast cancer, undergone lumpectomy and suggested chemotherapy by their doctor	Choice between having standard adjuvant chemotherapy or taking part in a clinical trial testing a new chemotherapy for early stage breast cancer	Values clarification method resulted in more use of personal values when evaluating attributes of options, somewhat less ambivalence, less uncertainty and did not change preferred option.
Pros and Cons	O'Connor and others 1999 [68]	n=201 women aged 50-69 who had never used hormone therapy	Whether or not to take hormone replacement therapy after menopause	Values clarification method had no effect on clarity of values, values congruence, total decisional conflict, other subscales of Decisional Conflict Scale, nor acceptability of intervention.
Pros and Cons	Paquin and others 2018 [69]	n=1000 people aged 18-44 who were pregnant or whose	Whether or not to use genomic sequencing to identify genetic	Values clarification method decreased parental beliefs against genomic sequencing.

		partner was pregnant or planning to become pregnant in the next 2 years	variants in one's child	
Pros and Cons	Peinado and others 2020 [10]	n=1000 people aged 18-44 who were pregnant or whose partner was pregnant or planning to become pregnant in the next 2 years	Whether or not to enroll their newborn child in a medical research study that would involve screening for genetic conditions	Values clarification method decreased decisional regret and increased clarity of personal values but had no effect on overall decisional conflict nor on intent to have one's child tested.
Pros and Cons	Witteman and others 2020 [48]	n=772 adults asked to imagine they had been diagnosed with colon cancer	Choice between two hypothetical surgeries for colon cancer	Values clarification method (strategy 4b in paper) reduced decisional conflict but did not change values congruence.
Rating Scales	Garvelink and others 2014*** [70]	n=271 healthy women	Whether or not to undergo fertility preserving procedures prior to cancer treatment	Values clarification method had no effect on knowledge nor decisional conflict.
Rating Scales	Kuppermann and others 2014 [71]	n=710 pregnant women who had not yet undergone screening or diagnostic testing for fetal aneuploidy in the current pregnancy	Whether or not to have any screening or diagnostic testing for fetal aneuploidy; if screening or testing is desired, whether to start with screening or with invasive diagnostic testing; and which specific screening and/or diagnostic test(s) to undergo.	Values clarification method increased patient knowledge and resulted in less invasive prenatal test use and more informed choices. Values clarification method did not change decisional conflict nor decisional regret.
Rating Scales (with and without decision analytic summary)	Feldman-Stewart and others 2006 [72]	n=90 male volunteers asked to imagine that they had just been diagnosed with early-stage prostate cancer	Choice between four options for early stage prostate cancer	Participants preferred values clarification method with decision analytic summary over values clarification method without summary and no values clarification method.
Rating Scales	Witteman and others 2020 [48]	n=785 adults asked to imagine they had been diagnosed with colon cancer	Choice between two hypothetical surgeries for colon cancer	Values clarification method (strategy 6a in paper) reduced decisional conflict but did not change values congruence.
Rating Scales + Ranking	Brenner and others 2014 [59]	n=614 people between the ages of 50 and 75 at average risk for colorectal cancer	Whether or not to be screened for colorectal cancer, and, if yes, what screening test to use	Values clarification method increased the importance placed on risk reduction as an important attribute but did not affect unlabeled test preference, values clarity, nor intent to be screened.
Rating Scales + Ranking	Pignone and others 2012 [60]	n=104 adults 48-75 at average risk for colon cancer	Whether or not to be screened for colorectal cancer, and, if yes, what screening test to use	Values clarification method influenced choice of most important attribute, but did not affect values clarity, intent to be screened, or choice of screening test.
Rating Scales + Ranking	Pignone and others 2013 [61]	n=609 men aged 50-70 at average risk of prostate cancer	Whether or not to be screened for prostate cancer	Values clarification method increased the importance placed on dying but did not influence intent to be screened.
Rating Scales + Ranking	Sheridan and others 2010 [73]	n=137 men aged 45-80 with no prior history of cardiovascular	Whether or not to initiate behaviours to prevent coronary heart disease, and, if so,	Values clarification method had no effect. Decisional conflict, perceived values congruence, and self-efficacy for health behaviours improved with and without

		disease	which behaviours	values clarification. Behavioural intentions did not change.
Time Tradeoff + Rating Scales	Frosch and others 2008 [74]	n=611 men older than 50 years	Whether or not to be screened for prostate cancer	Values clarification method increased cancer knowledge scores and decreased decisional conflict.

*n is given for the study as a whole. See supplementary appendix for further details about each study.
**Decision analysis or multicriteria decision analysis is an umbrella term. It encompasses some of the other, more specific categories (e.g., discrete choice experiments, best-worst scaling.) Throughout the paper, when applicable, we use the more specific, narrower categories. Otherwise, we use the umbrella term “multicriteria decision analysis,” or, for brevity in figures, “decision analysis.”
***Garvelink and colleagues 2014 and Witteman and colleagues 2020 each reported multiple experiments testing values clarification methods that did not differ in type nor in outcomes. Pooled results are therefore presented here.

Quality assessment

Overall study quality was acceptable, with the majority of studies at low risk of bias on most elements. Eight studies were deemed to be at high risk of bias on one element; the majority in Blinding of Participants and Personnel (Performance Bias). Eighteen additional studies were deemed unclear on this element. Blinding of Outcome Assessment (Detection Bias) was the next most common source of potential bias, with 1 study at high risk of bias and 20 more unclear. Full details of risk of bias assessments are available in Online Appendix 3.

Values Congruence

As shown in Figure 2a, included explicit values clarification methods, as a group, increased values congruence. Eleven out of 43 trials (26%) reported the number of people who made values-congruent or values-disgruent decisions. The pooled risk difference of making a values-disgruent decision when using one of the trialed values clarification methods was -0.04 95% CI [-0.06 to -0.02], p<.001. The I^2 of 28% indicates a relatively low level of statistical heterogeneity.

Figure 2b shows a statistically significant subgroup difference by type of values clarification method. The results suggest that decision analysis is more likely to encourage values-congruent decisions compared to other explicit values clarification methods within this set of trials (Chi-squared(2)=9.25, p=.01). The results show no significant subgroup differences by trade-offs, implementation, theory or by implication of the decision. (See Online Appendix 3.) There were no studies in this analysis with a high risk of bias.

Figure 2a. Values Congruence*: Overall (All Values Clarification Methods Together)



*Events refer to values-disgruent decisions. The meta-analysis synthesizes the risk across trials of making a values-disgruent decision.

Figure 2b. Values Congruence* by Type of Values Clarification Method



*Events refer to values-disgruent decisions. The meta-analysis synthesizes the risk across trials of making a values-disgruent decision.

Decisional Conflict

As shown in Figure 3a, explicit values clarification methods decrease decisional conflict. For the 14/43 (33%) trials for which we had complete data, the pooled standardized mean difference for decisional conflict was -0.20 95% CI [-0.29 to -0.11], p<0.001. The I^2 of 67% represents moderate to high statistical heterogeneity. Figure 3b shows there was no significant subgroup difference by type of values clarification method (Chi-squared(2)=6.08, p=.05). We found no significant subgroup differences by trade-offs, implementation, theory, implication, nor risk of bias (see Online Appendix 3).

Figure 3a. Decisional Conflict: Overall Measure



Figure 3b. Decisional Conflict by Type of Values Clarification Method



Head-to-Head Evaluations of Values Clarification Methods

The five studies that compared values clarification methods to each other reported findings that align with the findings of our meta-analyses. Methods that provided users with explicit feedback regarding how the decision options align with their stated values led to somewhat better outcomes, including greater values congruence. [48] When asked to compare methods to each other, study participants also preferred a values clarification method that explicitly showed them how the decision options align with their stated values. [72] Different values clarification methods yielded different patterns of attribute importance. [59–61] Brief summaries of each study are available in Online Appendix 3.

Discussion

Overall, our systematic review and meta-analyses confirm that explicit values clarification methods improve decision outcomes, notably by increasing values congruence and decreasing decisional conflict. Patient decision aids should include an explicit values clarification method.

While the best explicit values clarification method may depend on context—for example, urgent versus routine care or the extent to which a decision has a clear set of decision attributes—our analyses suggest that patient decision aid developers may wish to consider methods that draw on multicriteria decision analysis. The apparent advantages of such methods shown in our analyses may reflect similarities between the process and the outcome. In other words, increased values congruence yielded by decision analytic methods may be a function of the ways in which such methods transparently show people how their options align with their stated values. We additionally caution that when these methods use pre-specified attributes, there might not be the

flexibility for users to add new attributes, highlighting the importance of research to inform attribute selection. We acknowledge that some researchers have argued that health professionals having an unhurried, high-quality conversation with patients may be a preferred approach for at least some patients, especially when decision attributes are many and varied. However, in this systematic review, trials of Open Discussion values clarification methods did not demonstrate strong results, suggesting that such an ideal may be difficult to achieve.

To advance further knowledge on the merits and pitfalls of different values clarification methods, we recommend that authors of future trials of values clarification methods report four outcomes: decisional conflict, decision or decision intention, values congruence, and decisional regret. When possible, authors should make use of validated scales that have good psychometric properties and are commonly reported, as this facilitates evidence synthesis.

Decisional conflict should be assessed before people make the decision, using a version of the Decisional Conflict Scale. [75, 76] Decisions or decision intentions should be assessed when the decision is made.

Values congruence should be assessed once the decision is made. We acknowledge that including values congruence as an outcome brings both measurement and conceptual issues. Measurement issues exist because there are disagreements about how to measure what matters to people (or indeed, whether it is conceptually possible to do so) and compare such measures to what people choose. [77] Values congruence should not be measured using the values clarity subscale of the Decisional Conflict Scale, as this subscale measures perceived values clarity, not values congruence. [48] Further research is required to determine whether measuring values congruence might introduce bias or otherwise negatively influence decision making.

Decisional regret should be assessed with a version of the Decisional Regret Scale [78, 79] after people make the decision, ideally with a sufficiently long delay that longer-term effects can be captured. An included study in this review showed that a values clarification method reduced decisional regret, but only after a year had passed following implementation of the decision. [54]

For all four measures, authors should clearly report sample mean and sample standard deviation for continuous measures, numbers in each category for categorical measures, and sample size per study arm in all cases. Finally, we recommend that patient decision aid developers explain the rationale for their choice of values clarification method.

Our study has three main limitations. First, the included data were of moderate quality. Although this review includes many robust trials, the included studies often measured different outcomes or the same outcomes in different ways, there were missing data in some studies, some studies had high risk of bias (often because it was not possible to prevent study participants from ascertaining the study arm to which they were assigned), and some of our meta-analyses had high heterogeneity. Together, these issues suggest a degree of caution in our conclusions. Second, we did not distinguish between subtypes of values clarification methods. For example, different adaptive conjoint analysis exercises may be very different from each other, as might open discussions, or many other values clarification methods we grouped together, particularly those we grouped under the broad umbrella term of multicriteria decision analysis. Indeed, the values clarification methods used and trialed may simply reflect authors' interests and expertise. Given the breadth of methods available, further comparative effectiveness research is needed to conclusively determine the superiority of any given method. Third and finally, our primary findings were heavily influenced by studies conducted with relatively homogenous populations making hypothetical decisions. Although our sensitivity analyses suggested no differences

between studies in real and hypothetical contexts, we nonetheless believe further study is needed in more diverse populations making real decisions before drawing firmer conclusions.

Our study also has three main strengths. First, we catalog definitions and resources regarding values clarification methods, as well as recommended outcomes to report in studies. In doing so, we hope to offer more clarity and structure to a literature that can be confusing to navigate, particularly for those who are newer to developing patient decision aids. Second, we begin to answer a core question that commonly arises when developing a patient decision aid: when including a values clarification method, which type of method should one use? Third and finally, we used rigorous methods and an expansive, systematic search. By conducting a systematic review, we reduced our likelihood of missing relevant studies. By including meta-analyses, we offer stronger findings and recommendations than would be possible without pooling data across multiple studies.

In conclusion, patient decision aids should include an explicit values clarification method. Patient decision aid developers may wish to consider the potential advantages of multicriteria decision analysis. Future research should further investigate which methods lead to the best outcomes across or within particular decisions, populations, and settings. Authors of randomized controlled trials in this area should report decisional conflict, decision made, values congruence, and decisional regret.

DECLARATIONS

Abbreviations

None

Ethics Approval, Consent to Participate and Consent for Publication

Not applicable.

Availability of Data and Materials

Full data are available in the online appendices.

Competing Interests

None.

Funding

This study was funded by the Canadian Institutes of Health Research (CIHR) FDN-148426 (PI Witteman). HOW receives salary support from Tier 2 Canada Research Chair in Human-Centred Digital Health and received salary support during this study from a Fonds de Recherche du Québec-Santé (FRQS) Research Scholar Junior 2 Career Award. The CIHR, Canada Research Chairs program, and FRQS had no role in determining the study design, the plans for data collection or analysis, the decision to publish, nor the preparation of this manuscript.

Authors' Contributions

All authors contributed to the design of the study. HOW, RN, GV, SCD, SC, MM, TP, CR, CRB, JJ contributed to data collection. HOW, SCD, and JJ conducted data analysis and interpretation. HOW drafted the first version of the article with early revision by RN, GV, SCD, SC, MM, TP, CR, CRB, JJ and multiple subsequent revisions by all authors. All authors critically revised the article and approved the final version for submission for publication. HOW had full access to all the data in the study and had final responsibility for the decision to submit for publication. Authors BA, JFPB, SC, AF, TG, MM, AP, MP, TP, CR, DR, CRB, PT, MW, DBW, CEW contributed approximately equally and are listed alphabetically by last name.

Acknowledgements

The authors gratefully acknowledge Frédéric Bergeron, MLIS, for assistance with search strategy and Caroline Beaudoin for assistance in resolving article counts. We thank all authors of the original articles who generously gave their time to provide missing data when we were unable to extract the data needed from their papers.

References

[1] Marteau TM, Dormandy E, Michie S. A measure of informed choice. *Health Expect* 2001; 4: 99–108.

[2] Llewellyn-Thomas HA. Patients' health-care decision making: a framework for descriptive and experimental investigations. *Med Decis Making* 1995; 15: 101–106.

[3] Légaré F, Witteman HO. Shared decision making: examining key elements and barriers to adoption into routine clinical practice. *Health Aff* 2013; 32: 276–284.

[4] Hoffmann TC, Montori VM, Del Mar C. The connection between evidence-based medicine and shared decision making. *JAMA* 2014; 312: 1295–1296.

[5] Barrett B, McKenna P. Communicating benefits and risks of screening for prostate, colon, and breast cancer. *Fam Med* 2011; 43: 248–253.

[6] Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients' preferences matter. *BMJ* 2012; 345: e6572.

[7] Llewellyn-Thomas HA, Crump RT. Decision support for patients: values clarification and preference elicitation. *Med Care Res Rev* 2013; 70: 50S–79S.

[8] Munro S, Stacey D, Lewis KB, et al. Choosing treatment and screening options congruent with values: Do decision aids help? Sub-analysis of a systematic review. *Patient Educ Couns* 2016; 99: 491–500.

[9] Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Epub ahead of print 2017. DOI: 10.1002/14651858.CD001431.pub5.

[10] Peinado S, Paquin RS, Rini C, et al. Values clarification and parental decision making about newborn genomic sequencing. *Health Psychol*. Epub ahead of print 30 December 2019. DOI: 10.1037/hea0000829.

[11] Witteman HO, Scherer LD, Gavaruzzi T, et al. Design Features of Explicit Values Clarification Methods: A Systematic Review. *Med Decis Making* 2016; 36: 453–471.

[12] Witteman HO, Gavaruzzi T, Scherer LD, et al. Effects of Design Features of Explicit Values Clarification Methods: A Systematic Review. *Med Decis Making* 2016; 36: 760–776.

[13] Bridges JFP, Brett Hauber A, Marshall D, et al. Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. *Value in Health* 2011; 14: 403–413.

[14] Ho M, Saha A, McCleary KK, et al. A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies. *Value Health* 2016; 19: 746–750.

[15] Kristensen FB, Husereau D, Huić M, et al. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. *Value in Health* 2019; 22: 13–20.

[16] O'Connor A, Llewellyn-Thomas H, Dolan J, et al. Section D: Clarifying and Expressing Values. In: O'Connor A, Llewellyn-Thomas H, Stacey D (eds) *IPDAS Collaboration Background Document*. International Patient Decision Aids Standards (IPDAS) Collaboration, 2005, pp. 17–23.

[17] Fagerlin A, Pignone M, Abhyankar P, et al. Clarifying values: an updated review. *BMC Med Inform Decis Mak* 2013; 13 Suppl 2: S8.

[18] Charles C, Gafni A. The vexing problem of defining the meaning, role and measurement of values in treatment decision-making. *J Comp Eff Res* 2014; 3: 197–209.

[19] Lim C, Berry ABL, Hirsch T, et al. Understanding What Is Most Important to Individuals with Multiple Chronic Conditions: A Qualitative Study of Patients' Perspectives. *J Gen Intern Med* 2017; 32: 1278–1284.

[20] Rocque R, Chipenda Dansokho S, Grad R, et al. What Matters to Patients and Families: A Content and Process Framework for Clarifying Preferences, Concerns, and Values. *Med Decis Making* 2020; 272989X20940660.

[21] Patient Preference Information – Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Food and Drug Administration, https://www.fda.gov/media/92593/download (24 August 2016).

[22] Pieterse AH, de Vries M, Kunneman M, et al. Theory-informed design of values clarification methods: a cognitive psychological perspective on patient health-related decision making. *Soc Sci Med* 2013; 77: 156–163.

[23] de Vries M, Fagerlin A, Witteman HO, et al. Combining deliberation and intuition in patient decision support. *Patient Educ Couns* 2013; 91: 154–160.

[24] Fischhoff B, Barnato AE. Value Awareness: A New Goal for End-of-life Decision Making. *MDM Policy & Practice* 2019; 4: 2381468318817523.

[25] Ali S, Ronaldson S. Ordinal preference elicitation methods in health economics and health services research: using discrete choice experiments and ranking methods. *Br Med Bull* 2012; 103: 21–44.

[26] Whitty JA, Lancsar E, Rixon K, et al. A systematic review of stated preference studies reporting public preferences for healthcare priority setting. *Patient* 2014; 7: 365–386.

[27] Pieterse AH, Berkers F, Baas-Thijssen MCM, et al. Adaptive Conjoint Analysis as individual preference assessment tool: feasibility through the internet and reliability of preferences. *Patient Educ Couns* 2010; 78: 224–233.

[28] Bansback N, Li LC, Lynd L, et al. Development and preliminary user testing of the DCIDA (dynamic computer interactive decision application) for 'nudging'patients towards high quality decisions. *BMC Med Inform Decis Mak* 2014; 14: 1–13.

[29] Dolan JG, Boohaker E, Allison J, et al. Patients' preferences and priorities regarding colorectal cancer screening. *Med Decis Making* 2013; 33: 59–70.

[30] Ungar WJ, Hadioonzadeh A, Najafzadeh M, et al. Quantifying preferences for asthma control in parents and adolescents using best-worst scaling. *Respir Med* 2014; 108: 842–851.

[31] Thokala P, Devlin N, Marsh K, et al. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. *Value Health* 2016; 19: 1–13.

[32] Regier DA, Peacock S. Theoretical Foundations of MCDA. In: Marsh K, Goetghebeur M, Thokala P, et al. (eds) *Multi-Criteria Decision Analysis to Support Healthcare Decisions*. Cham: Springer International Publishing, 2017, pp. 9–28.

[33] Hazlewood GS, Marshall DA, Barber CEH, et al. Using a Discrete-Choice Experiment in a Decision Aid to Nudge Patients Towards Value-Concordant Treatment Choices in Rheumatoid Arthritis: A Proof-of-Concept Study. *Patient Prefer Adherence* 2020; 14: 829–838.

[34] Weir KR, Bonner C, McCaffery K, et al. Pharmacists and patients sharing decisions about medicines: Development and feasibility of a conversation guide. *Res Social Adm Pharm* 2019; 15: 682–690.

[35] Ottawa Personal Decision Guides - Patient Decision Aids - Ottawa Hospital Research Institute, https://decisionaid.ohri.ca/decguide.html (accessed 4 November 2020).

[36] Masya LM, Young JM, Solomon MJ, et al. Preferences for outcomes of treatment for rectal cancer: patient and clinician utilities and their application in an interactive computer-based decision aid. *Dis Colon Rectum* 2009; 52: 1994–2002.

[37] Heckerling PS, Verp MS, Albert N. Patient or physician preferences for decision analysis: the prenatal genetic testing decision. *Med Decis Making* 1999; 19: 66–77.

[38] Jibaja-Weiss ML, Volk RJ. Utilizing computerized entertainment education in the development of decision aids for lower literate and naive computer users. *J Health Commun* 2007; 12: 681–697.

[39] Stiggelbout AM, Kiebert GM, Kievit J, et al. Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. *Med Decis Making* 1994; 14: 82–90.

[40] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6: e1000097.

[41] Higgins JPT, Green S (eds). *Cochrane handbook for systematic reviews for interventions*, https://handbook-5-1.cochrane.org/front_page.htm (2011).

[42] Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557–560.

[43] de Achaval S, Fraenkel L, Volk RJ, et al. Impact of educational and patient decision aids on decisional conflict associated with total knee arthroplasty. *Arthritis Care Res* 2012; 64: 229–237.

[44] Fraenkel L, Rabidou N, Wittink D, et al. Improving informed decision-making for patients with knee pain. *J Rheumatol* 2007; 34: 1894–1898.

[45] Hess LM, Litwiller A, Byron J, et al. Preference elicitation tool for abnormal uterine bleeding treatment: a randomized controlled trial. *Patient* 2015; 8: 217–227.

[46] Hutyra CA, Smiley S, Taylor DC, et al. Efficacy of a Preference-Based Decision Tool on Treatment Decisions for a First-Time Anterior Shoulder Dislocation: A Randomized Controlled Trial of At-Risk Patients. *Med Decis Making* 2019; 39: 253–263.

[47] Jayadevappa R, Chhatre S, Gallo JJ, et al. Treatment preference and patient centered prostate cancer care: Design and rationale. *Contemp Clin Trials* 2015; 45: 296–301.

[48] Witteman HO, Julien A-S, Ndjaboue R, et al. What Helps People Make Values-Congruent Medical Decisions? Eleven Strategies Tested across 6 Studies. *Med Decis Making* 2020; 40: 266–278.

[49] Myers RE. *Value-based decision-making in prostate cancer early detection*. DAMD17-98-1-8641, Thomas Jefferson University, November 2003.

[50] Myers RE, Daskalakis C, Cocroft J, et al. Preparing African-American men in community primary care practices to decide whether or not to have prostate cancer screening. *J Natl Med Assoc* 2005; 97: 1143–1154.

[51] Shirk JD, Crespi CM, Saucedo JD, et al. Does Patient Preference Measurement in Decision Aids Improve Decisional Conflict? A Randomized Trial in Men with Prostate Cancer. *Patient*. Epub ahead of print 16

June 2017. DOI: 10.1007/s40271-017-0255-7.

[52] Bekker HL, Hewison J, Thornton JG. Applying decision analysis to facilitate informed decision making about prenatal diagnosis for Down syndrome: a randomised controlled trial. *Prenat Diagn* 2004; 24: 265–275.

[53] Clancy CM, Cebul RD, Williams SV. Guiding individual decisions: a randomized, controlled trial of decision analysis. *Am J Med* 1988; 84: 283–288.

[54] Feldman-Stewart D, Tong C, Siemens R, et al. The Impact of Explicit Values Clarification Exercises in a Patient Decision Aid Emerges After the Decision Is Actually Made. *Medical Decision Making* 2012; 32: 616–626.

[55] Hopkin G, Au A, Collier VJ, et al. Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection. *Med Decis Making* 2019; 39: 264–277.

[56] Montgomery AA, Fahey T, Peters TJ. A factorial randomised controlled trial of decision analysis and an information video plus leaflet for newly diagnosed hypertensive patients. *Br J Gen Pract* 2003; 53: 446–453.

[57] Montgomery AA, Emmett CL, Fahey T, et al. Two decision aids for mode of delivery among women with previous caesarean section: Randomized controlled trial. *BMJ: British Medical Journal* 2007; 334: 1305–1309.

[58] Witteman HO, Chipenda Dansokho S, Exe N, et al. Risk Communication, Values Clarification, and Vaccination Decisions. *Risk Anal* 2015; 35: 1801–1819.

[59] Brenner A, Howard K, Lewis C, et al. Comparing 3 values clarification methods for colorectal cancer screening decision-making: a randomized trial in the US and Australia. *J Gen Intern Med* 2014; 29: 507–513.

[60] Pignone MP, Brenner AT, Hawley S, et al. Conjoint analysis versus rating and ranking for values elicitation and clarification in colorectal cancer screening. *J Gen Intern Med* 2012; 27: 45–50.

[61] Pignone MP, Howard K, Brenner AT, et al. Comparing three techniques for eliciting patient values for decision making about prostate-specific antigen screening: a randomized controlled trial. *JAMA Intern Med* 2013; 173: 362–368.

[62] Au DH, Udris EM, Engelberg RA, et al. A randomized trial to improve communication about end-of-life care among patients with COPD. *Chest* 2012; 141: 726–735.

[63] Epstein AS, O'Reilly EM, Shuk E, et al. A Randomized Trial of Acceptability and Effects of Values-Based Advance Care Planning in Outpatient Oncology: Person-Centered Oncologic Care and Choices. *J Pain Symptom Manage* 2018; 56: 169–177.e1.

[64] Kennedy ADM, Sculpher MJ, Coulter A, et al. Effects of Decision Aids for Menorrhagia on Treatment Choices, Health Outcomes, and Costs: a randomized controlled trial. *JAMA* 2002; 288: 2701.

[65] Lerman C, Biesecker B, Benkendorf JL, et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. *J Natl Cancer Inst* 1997; 89: 148–157.

[66] Matheis-Kraft C, Roberto KA. Influence of a values discussion on congruence between elderly women and their families on critical health care decisions. *J Women Aging* 1997; 9: 5–22.

[67] Abhyankar P, Bekker HL, Summers BA, et al. Why values elicitation techniques enable people to make informed decisions about cancer trial participation. *Health Expect* 2011; 14 Suppl 1: 20–32.

[68] O'Connor RN AM, Wells GA, Frcp PTMD, et al. The effects of an 'explicit' values clarification exercise in a woman's decision aid regarding postmenopausal hormone therapy. *Health Expectations* 1999; 21–32.

[69] Paquin RS, Peinado S, Lewis MA, et al. A behavior-theoretic evaluation of values clarification on parental beliefs and intentions toward genomic sequencing for newborns. *Soc Sci Med* 2018; 112037.

[70] Garvelink MM, ter Kuile MM, Stiggelbout AM, et al. Values clarification in a decision aid about fertility preservation: does it add to information provision? *BMC Med Inform Decis Mak* 2014; 14: 68.

[71] Kuppermann M, Pena S, Bishop JT, et al. Effect of enhanced information, values clarification, and removal of financial barriers on use of prenatal genetic testing: a randomized clinical trial. *JAMA* 2014; 312: 1210–1217.

[72] Feldman-Stewart D, Brennenstuhl S, Brundage MD, et al. An explicit values clarification task: development and validation. *Patient Educ Couns* 2006; 63: 350–356.

[73] Sheridan SL, Griffith JM, Behrend L, et al. Effect of adding a values clarification exercise to a decision aid on heart disease prevention: a randomized trial. *Med Decis Making* 2010; 30: E28–39.

[74] Frosch D, Bhatnagar V, Tally S, et al. Internet patient decision support. *Arch Intern Med* 2008; 168: 363–369.

[75] O'Connor AM. *User Manual – Decisional Conflict Scale*. University of Ottawa, https://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf (2010).

[76] Decisional conflict scale - evaluation measures - patient decision aids - Ottawa hospital research institute, https://decisionaid.ohri.ca/eval_dcs.html (accessed 20 January 2021).

[77] Winn K, Ozanne E, Sepucha K. Measuring patient-centered care: An updated systematic review of how studies define and report concordance between patients' preferences and medical treatments. *Patient Educ Couns* 2015; 98: 811–821.

[78] Brehaut JC, O'Connor AM, Wood TJ, et al. Validation of a decision regret scale. *Med Decis Making* 2003; 23: 281–292.

[79] Decision regret scale - evaluation measures - patient decision aids - Ottawa hospital research institute, https://decisionaid.ohri.ca/eval_regret.html (accessed 20 January 2021).

Online Appendix 1: Search Strategies

#1	((value? OR patient preference? OR treatment preference?) adj5 (clarif* OR elicit*)).ti,ab,kw
#2	(Decision Making/ AND Social Values/)
#3	MCDA.ti,ab
#4	analytical hierarchy process.ti,ab,kw
#5	best-worst scaling.ti,ab,kw
#6	((conjoint OR decision) adj3 analysis):ti,ab,kw
#7	data envelopment analysis.ti,ab,kw
#8	Decision conferencing.ti,ab,kw
#9	Decision models.ti,ab,kw
#10	direct rating.ti,ab,kw
#11	points allocation.ti,ab,kw
#12	discrete choice experiment.ti,ab ,kw
#13	("dominance-based" adj3 approach*).ti,ab,kw
#14	EVIDEM framework.ti,ab,kw
#15	(geometrical analysis for interactive aid OR GAIA).ti,ab,kw
#16	MACBETH.ti,ab,kw
#17	("Measuring Attractiveness" adj4 "Categorical Based Evaluation TecHnique").ti,ab,kw
#18	Multi-Attribute Global Inference of Quality.ti,ab,kw
#19	(("Multiple attribute" OR "multiple criteria" OR multiattribute) adj2 (utility OR theory OR analysis)).ti,ab,kw
#20	(MAUT OR MAVT OR MCUA OR MCA).ti,ab,kw
#21	("Novel approach to imprecise assessment and decision environments" OR NAIADE).ti,ab,kw
#22	ORESTE.ti,ab,kw
#23	Pairwise comparisons.ti,ab,kw
#24	PAPRIKA.ti,ab,kw
#25	Pairwise RanKings.ti,ab,kw
#26	PROMETHEE.ti,ab,kw
#27	Preference Ranking Organization Method for Enrichment of Evaluations.ti,ab,kw
#28	QUALItative FLEXible.ti,ab,kw
#29	Simple Multi Attribute Rating Technique.ti,ab,kw
#30	SMART.ti,ab,kw
#31	Standard gamble.ti,ab,kw
#32	Swing weighting.ti,ab,kw
#33	TOPSIS.ti,ab,kw

#34 Technique for Order Preference by Similarity to the Ideal Solution.ti,ab,kw
#35 (Time tradeoff OR time tradeoff).ti,ab ,kw
#36 Value function methods.ti,ab,kw
#37 Valutazione delle Tecnologie Sanitarie.ti,ab,kw
#38 VDA.ti,ab,kw
#39 VTS.ti,ab,kw
#40 verbal decision analysis.ti,ab,kw
#41 visual analog scale.ti,ab,kw
#42 willingness-to-pay.ti,ab,kw
#43 ((Scoring OR weighting) adj1 methods).ti,ab,kw
#44 REGIME.ti,ab,kw
#45 (scal* adj2 (methods OR Natural OR Constructed OR Objective)).ti,ab,kw
#46 OR/3-45
#47 Randomized Controlled Trials as Topic/
#48 randomized controlled trial/
#49 Random Allocation/
#50 Double Blind Method/
#51 Single Blind Method/
#52 clinical trial/
#53 clinical trial, phase i.pt
#54 clinical trial, phase ii.pt
#55 clinical trial, phase iii.pt
#56 clinical trial, phase iv.pt
#57 controlled clinical trial.pt
#58 randomized controlled trial.pt
#59 multicenter study.pt
#60 clinical trial.pt
#61 exp Clinical Trials as topic/
#62 (clinical adj trial$).tw
#63 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw
#64 PLACEBOS/
#65 placebo$.tw
#66 randomly allocated.tw

#67 (allocated adj2 random$).tw

#68 OR/47-67

#69 (#1 OR #2 OR #46) AND #68

#70 #70 NOT (animals/ NOT humans/)

#1	((value* OR "patient preference" OR "treatment preferences") NEAR/5 (clarif* OR elicit*)):ti,ab,kw
#2	'decision support system'/de OR 'patient decision making'/de
#3	MCDA:ti,ab,kw
#4	"analytical hierarchy process":ti,ab,kw
#5	"best-worst scaling":ti,ab,kw
#6	((conjoint OR decision) NEAR/3 analysis):ti,ab,kw
#7	"data envelopment analysis":ti,ab,kw
#8	"Decision conferencing":ti,ab,kw
#9	"Decision models":ti,ab,kw
#10	"direct rating":ti,ab,kw
#11	"points allocation":ti,ab,kw
#12	"discrete choice experiment":ti,ab,kw
#13	("dominance-based" NEAR/3 approach*):ti,ab,kw
#14	"EVIDEM framework":ti,ab,kw
#15	"geometrical analysis for interactive aid OR GAIA":ti,ab,kw
#16	MACBETH:ti,ab,kw
#17	("Measuring Attractiveness" NEAR/4 "Categorical Based Evaluation TecHnique"):ti,ab,kw
#18	"Multi-Attribute Global Inference of Quality":ti,ab,kw
#19	(("Multiple attribute" OR "multiple criteria" OR multiattribute) NEAR/2 (utility OR theory OR analysis)):ti,ab,kw
#20	(MAUT OR MAVT OR MCUA OR MCA):ti,ab,kw
#21	("Novel approach to imprecise assessment and decision environments" OR NAIADE):ti,ab,kw
#22	ORESTE:ti,ab,kw
#23	"Pairwise comparisons":ti,ab,kw
#24	PAPRIKA:ti,ab,kw
#25	"Pairwise RanKings":ti,ab,kw
#26	PROMETHEE:ti,ab,kw
#27	"Preference Ranking Organization Method for Enrichment of Evaluations":ti,ab,kw
#28	"QUALItative FLEXible":ti,ab,kw
#29	"Simple Multi Attribute Rating Technique":ti,ab,kw
#30	SMART:ti,ab,kw
#31	"Standard gamble":ti,ab,kw
#32	"Swing weighting":ti,ab,kw
#33	TOPSIS:ti,ab,kw

#34 "Technique for Order Preference by Similarity to the Ideal Solution":ti,ab,kw
#35 ("Time tradeoff" OR "time tradeoff"):ti,ab,kw
#36 "Value function methods":ti,ab,kw
#37 "Valutazione delle Tecnologie Sanitarie":ti,ab,kw
#38 VDA:ti,ab,kw
#39 VTS:ti,ab,kw
#40 "verbal decision analysis":ti,ab,kw
#41 "visual analog scale":ti,ab,kw
#42 "willingness-to-pay":ti,ab,kw
#43 ((Scoring OR weighting) NEAR/1 methods):ti,ab,kw
#44 REGIME:ti,ab,kw
#45 (scal* NEAR/2 (methods OR Natural OR Constructed OR Objective)):ti,ab,kw
#46 #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #
#47 'clinical trial'/de
#48 'randomized controlled trial'/de
#49 'randomization'/de
#50 'single blind procedure'/de
#51 'double blind procedure'/de
#52 'crossover procedure'/de
#53 'placebo'/de OR 'prospective study'/de
#54 (randomi?ed NEXT/1 controlled NEXT/1 trial):ab,ti
#55 rct:ab,ti OR 'random allocation':ab,ti
#56 'randomly allocated':ab,ti OR 'allocated randomly':ab,ti
#57 (allocated NEAR/2 random):ab,ti
#58 ((single OR double OR treble OR triple) NEXT/1 blind*):ab,ti
#59 placebo*:ab,ti
#60 #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59
#61 (#1 OR #2 OR #46) AND #60
#62 #61 NOT (animal:de NOT human:de)
#63 [embase]/lim NOT ([embase]/lim AND [medline]/lim)

#1 ((value* OR "patient preference*" OR "treatment preference*") NEAR/5 (clarif* OR elicit*)):ti,ab
#2 ("Decision Making":kw AND "Social Values":kw)
#3 MCDA:ti,ab
#4 "analytical hierarchy process":ti,ab
#5 best-worst scaling:ti,ab
#6 ((conjoint OR decision) NEAR/3 analysis):ti,ab
#7 "Decision conferencing":ti,ab
#8 "Decision models":ti,ab
#9 "direct rating":ti,ab
#10 "points allocation":ti,ab
#11 "discrete choice experiment":ti,ab
#12 ("dominance-based" NEAR/3 approach*):ti,ab
#13 "Elimination and Choice Expressing Reality":ti,ab
#14 "EVIDEM framework":ti,ab
#15 "geometrical analysis for interactive aid" OR GAIA:ti,ab
#16 MACBETH:ti,ab
#17 ("Measuring Attractiveness" NEAR/4 "Categorical Based Evaluation TecHnique"):ti,ab
#18 "Multi-Attribute Global Inference of Quality":ti,ab
#19 "multiattribute objective function specification":ti,ab
#20 (("Multiple attribute" OR "multiple criteria" OR multiattribute) NEAR/2 (utility OR theory OR analysis)):ti,ab
#21 (MAUT OR MAVT OR MCUA OR MCA):ti,ab
#22 ("Novel approach to imprecise assessment and decision environments" OR NAIADE):ti,ab
#23 ORESTE:ti,ab
#24 "Pairwise comparisons":ti,ab
#25 PAPRIKA:ti,ab
#26 "Pairwise RanKings":ti,ab
#27 PROMETHEE:ti,ab
#28 "Preference Ranking Organization Method for Enrichment of Evaluations":ti,ab
#29 "QUALItative FLEXible":ti,ab
#30 "Simple Multi Attribute Rating Technique":ti,ab
#31 SMART:ti,ab
#32 "Standard gamble":ti,ab
#33 "Swing weighting":ti,ab

#34 TOPSIS:ti,ab
#35 "Technique for Order Preference by Similarity to the Ideal Solution":ti,ab
#36 ("Time tradeoff" OR "time tradeoff"):ti,ab
#37 "Value function methods":ti,ab
#38 "Valutazione delle Tecnologie Sanitarie":ti,ab
#39 VDA:ti,ab
#40 VTS:ti,ab
#41 "verbal decision analysis":ti,ab
#42 "visual analog scale":ti,ab
#43 "willingness-to-pay":ti,ab
#44 scoring method*:ti,ab OR "weighting method*":ti,ab
#45 REGIME:ti,ab
#46 (scal* NEAR/2 (methods OR Natural OR Constructed OR Objective)):ti,ab
#47 {OR #3-#46}
#48 #1 OR #2 OR #47

#1 TS=(((value$ OR "patient preference$" OR "treatment preference$") NEAR/5 (clarif* OR elicit*)))

#2 TS=((conjoint OR decision) NEAR/3 analysis)

#3 TS=(MCDA)

#4 TS=("analytical hierarchy process")

#5 TS=("best-worst scaling")

#6 TS=("data envelopment analysis")

#7 TS=("Decision conferencing")

#8 TS=("Decision models")

#9 TS=("direct rating")

#10 TS=("points allocation")

#11 TS=("discrete choice experiment")

#12 TS=("dominance-based" NEAR/3 approach*)

#13 TS=("Elimination and Choice Expressing Reality")

#14 TS=("EVIDEM framework")

#15 TS=("geometrical analysis for interactive aid" OR GAIA)

#16 TS=(MACBETH)

#17 TS= ("Measuring Attractiveness" NEAR/4 "Categorical Based Evaluation TecHnique")

#18 TS=("Multi-Attribute Global Inference of Quality")

#19 TS=(("Multiple attribute" OR "multiple criteria" OR multiattribute) NEAR/2 (utility OR theory OR analysis))

#20 TS=(MAUT OR MAVT OR MCUA OR MCA)

#21 TS=("Novel approach to imprecise assessment and decision environments" OR NAIADE)

#22 TS=(ORESTE)

#23 TS=("Pairwise comparisons")

#24 TS=(PAPRIKA)

#25 TS=("Pairwise RanKings")

#26 TS=(PROMETHEE)

#27 TS=("Preference Ranking Organization Method for Enrichment of Evaluations")

#28 TS=("QUALItative FLEXible")

#29 TS=("Simple MultiAttribute Rating Technique")

#30 TS=(SMART)

#31 TS=("Standard gamble")

#32 TS=(TOPSIS)

#33 TS=("Technique for Order Preference by Similarity to the Ideal Solution")

#34 TS=("time tradeoff" OR "time tradeoff")

#35 TS=("Value function methods")

#36 TS=("Valutazione delle Tecnologie Sanitarie")

#37 TS=(VDA)

#38 TS=(VTS)

#39 TS=("verbal decision analysis")

#40 TS=("visual analog scale")

#41 TS=("willingness-to-pay")

#42 TS= ((Scoring OR weighinng) NEAR/1 methods)

#43 TS=(REGIME)

#44 TS=(scal* NEAR/2 (methods OR Natural OR Constructed OR Objective))

#44 OR #43 OR #42 OR #41 OR #40 OR #39 OR #38 OR #37 OR #36 OR #35 OR #34 OR #33 OR #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR #26 OR #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR

#45 #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2

#46 "clinical trial"

#47 randomization

#48 "crossover procedure"

#49 placebo

#50 "prospective study"

#51 (randomi$ed NEAR/1 "controlled trial")

#52 rct

#53 (allocat* NEAR/2 random*)

#54 ((single OR double OR treble OR triple) NEAR/1 blind*))

#55 #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 #54

#56 (#1 OR #45) AND #55

#1 TI ((value# OR "patient preference#" OR "treatment preference#") N5 ((clarif* OR elicit*))

#2 AB ((value# OR "patient preference#" OR "treatment preference#") N5 ((clarif* OR elicit*))

#3 MH "Values Clarification"

#4 MM "Decision Support Techniques"

#5 TI ((conjoint OR decision) N3 analysis) OR AB ((conjoint OR decision) N3 analysis)

#6 TI MCDA OR AB MCDA

#7 TI "analytical hierarchy process" OR AB "analytical hierarchy process"

#8 TI "best-worst scaling" OR AB "best-worst scaling"

#9 TI "data envelopment analysis" OR AB "data envelopment analysis"

#10 TI "Decision conferencing" OR AB "Decision conferencing"

#11 TI "Decision models" OR AB "Decision models"

#12 TI "direct rating" OR AB "direct rating"

#13 TI "points allocation" OR AB "points allocation"

#14 TI "discrete choice experiment" OR AB "discrete choice experiment"

#15 TI ("dominance-based" N3 approach*) OR AB ("dominance-based" N3 approach*)

#16 TI "Elimination and Choice Expressing Reality" OR AB "Elimination and Choice Expressing Reality"

#17 TI "EVIDEM framework" OR AB "EVIDEM framework"

#18 TI "geometrical analysis for interactive aid" OR GAIA OR AB "geometrical analysis for interactive aid" OR GAIA

#19 TI MACBETH OR AB MACBETH

#20 TI ("Measuring Attractiveness" N4 "Categorical Based Evaluation TecHnique") OR AB ("Measuring Attractiveness" N4 "

#21 TI (("Multiple attribute" OR "multiple criteria" OR multiattribute) N2 (utility OR theory OR analysis)) OR AB (("Multiple

#22 TI (MAUT OR MAVT OR MCUA OR MCA) OR AB (MAUT OR MAVT OR MCUA OR MCA)

#23 TI ORESTE OR AB ORESTE

#24 TI "Pairwise comparisons" OR AB "Pairwise comparisons"

#25 TI PAPRIKA OR AB PAPRIKA

#26 TI "Pairwise RanKings" OR AB "Pairwise RanKings"

#27 TI SMART OR AB SMART

#28 TI "Standard gamble" OR AB "Standard gamble"

#29 TI "Swing weighting" OR AB "Swing weighting"

#30 TI TOPSIS OR AB TOPSIS

#31 TI "Technique for Order Preference by Similarity to the Ideal Solution" OR AB "Technique for Order Preference by Simi

#32 TI ("Time tradeoff" OR "time tradeoff") OR AB ("Time tradeoff" OR "time tradeoff")

#33 TI VDA OR AB VDA

#34 TI VTS OR AB VTS
#35 TI "visual analog scale" OR AB "visual analog scale"
#36 TI "willingness-to-pay" OR AB "willingness-to-pay"
#37 TI Scoring OR "weighting method#" OR AB Scoring OR "weighting method#"
#38 TI REGIME OR AB REGIME
#39 TI (scal* N2 (methods OR Natural OR Constructed OR Objective)) OR AB (scal* N2 (methods OR Natural OR Constructe
#40 (S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR
#41 TX allocat* random*
#42 MH "Quantitative Studies"
#43 MH "Placebos"
#44 TX placebo*
#45 TX random* allocat*
#46 MH "Random Assignment"
#47 TX randomi* control* trial*
#48 TX ((singl* n1 blind*) OR (singl* n1 mask*))
#49 TX ((doubl* n1 blind*) OR (doubl* n1 mask*))
#50 TX ((tripl* n1 blind*) OR (tripl* n1 mask*))
#51 TX ((trebl* n1 blind*) or (trebl* n1 mask*))
#52 TX (clinic* n1 trial*)
#53 PT "Clinical trial"
#54 MH "Clinical Trials+"
#55 #52 OR #65
#56 (#1 OR #2 OR #3 OR #4 OR #40) AND #55

Online Appendix 2: Further Study Details

ARTICLE					DECISION						VCM											STUDY DETAILS					
Paper ID (write text)	Corresponding author last name (write text)	Corresponding author email (write text)	Year of pub (write number)	Title (write text)	Context - 1 = screening; - 2 = diagnostic testing; - 3 = genetic testing; - 4 = prevention; - 5 = treatment; - 6 = unclear	Options - 1 = choosing to take option or not; - 2 = choosing between two or more options - 3 = choosing to take option or not AND choosing between two or more options; - 4 = unclear	Number of options (write number)	Details (write text)	Type - 1 = real; - 2 = hypothetical; - 3 = unclear	Clinical context (write text)	Theory, framework or underlying mechanism reported in the paper (write text)	Position in a DA (write text, e.g. in a DA before, after or between information sections, as a separate tool, etc.)	Media (write text)	Type (using the Witteman et al classification)	TYPE (for summary & use in paper)	Sub-type	Type (short version) (write text; copy-paste what is explicitly reported in the paper)	Type (long version) (write text; copy-paste what is explicitly reported in the paper)	Tradeoffs - 1 = Explicit; - 2 = Implied; - 3 = Both - 4 = Not at all	Presentation of results (implementation) - 1 =Yes (prior decision intention) - 2 =Yes (after decision intention) - 3 = No - 4 = Unclear	VCM intended to be completed independently or with others? (write text)	Population (write text)	Total Sample size (write number)	Total Sample size (comments)	Type(s) of comparison(s) relevant to evaluation of VCMs (write text)	Comparison (write text)	Summary of findings (write text)
Abhyankar 2010	Abhyankar	purva.abhyankar@stir.ac.uk	2010	Why values elicitation techniques enable people to make informed decisions about cancer trial participation	5	2	2	Choice between having standard adjuvant chemotherapy or taking part in a clinical trial testing a new chemotherapy for early stage breast cancer.	2	Cancer - breast	VCM development was guided by the information processing paradigm.	After information section about adjuvant chemotherapy and trial (i.e. after they had read the detailed information but before they were asked for their final decision).	Paper	Pros and cons	Pros and Cons	Binary	The values clarification tasks involved a paper-based summary of the benefits and risks information for both the options situated on either side of a weigh-scale. Women performed either an implicit or an explicit task.	The values clarification tasks involved a paper-based summary of the benefits and risks information for both the options situated on either side of a weigh-scale as outlined by O Connor et al. The implicit task asked women to: (i) review this information; (ii) add any other reasons for choosing or not choosing the options in the space provided; (iii) underline the benefits and risks they thought were more likely to happen. In addition to the steps performed in the implicit task, the explicit task asked women to: (iv) indicate the extent to which each benefit and risk mattered to them using stars (zero stars if it did not matter at all and five if it mattered a lot); (v) indicate their leaning towards taking part in the trial or having the standard treatment on a seven-point scale.	3	3	Independently	Healthy women aged 19-60 (mean = 36 years, SD = 13.8), staff or students at a UK university, asked to imagine having been diagnosed with breast cancer, undergone lumpectomy and suggested chemotherapy by their doctor.	30		No VCM (control) vs implicit VCM vs. explicit VCM	Randomized: 1) information only; 2) information plus "implicit" VCM (review benefits and risks, add to list if desired, underline events perceived as most likely); 3) information plus "explicit" VCM (implicit tasks plus rate importance of each benefit and risk and indicate direction leaning).	VCM resulted in more use of personal values when evaluating attributes of options, somewhat less ambivalence, less uncertainty and did not change decision preference.
Au 2012	Au	David.Au@VA.gov	2012	A Randomized Trial to Improve Communication About End-of-Life Care Among Patients With COPD	5	3	Numerous	Personal preferences for end-of-life care (i.e. desire for communication about advance care planning, patient-specific barriers and facilitators to communication about end-of-life care, preferences for CPR and mechanical ventilation, and the severity of their airflow limitation).	1	Lung disease - COPD	Social cognitive theory	n/a - not a DA	Verbal (and computer generated paper feedback forms).	List of concerns	List of Concerns	Discuss only	A one-page patient-specific feedback form that patients reviewed and shared with their surrogate(s).	One-page patient-specific feedback form providing the patient's three most important preferences for end-of-life experiences that can be reviewed and shared with their surrogate(s).	4	4	Independently with research assistants available to assist.	Patients with COPD (and their clinicians).	306		No VCM (control) vs VCM (intervention)	Cluster randomized trial using stratified random sampling procedures to assign clinicians (and their patients) to either the control or intervention or group.	A one-page patient-specific feedback form about preferences for end-of-life care and communication improved the occurrence and quality of communication from the patients' perspectives.
Bekker 2004	Bekker	h.l.bekker@leeds.ac.uk	2004	Applying decision analysis to facilitate informed decision making about prenatal diagnosis for Down syndrome: a randomised controlled trial	2	1	2	Whether or not to have a prenatal diagnosis for Down syndrome.	1	Prenatal screening - Down syndrome	Subjective expected-utility theory (SEU).	n/a - not a DA	Verbal (utterances were then transcribed and coded) and computer based (threshold graph)	Math based model	Decision Analysis	Decision analysis	A decision tree and verbal prompts, and a threshold graph.	A decision tree representing test options and consequences; a verbal prompt eliciting a global utility (i.e. the balance point between the burden of having a child with Down syndrome and that of pregnancy termination), and; a threshold graph integrating the utility and MSS risk figure to identify the alternative with the greatest expected utility.	1	1	With a counselor	Pregnant women receiving a screen positive maternal serum screening result (risks ≥ 1 in 250).	106	117 recruited complete data for 106	No VCM (routine consultation) vs VCM (routine information + decision analysis consultation)	Randomised controlled trial design with two trial arms: 1) routine consultation; 2) decision analysis consultation. Participants were randomly allocated to one of the two consultations using previously numbered, sealed, opaque envelopes.	Decision analysis consultations enable women to make more informed prenatal diagnosis decisions. Professionals will need training to use this technique effectively.
Brenner 2014 (1 of 3)	Brenner	alison.brenner@unc.edu	2013	Comparing 3 Values Clarification Methods for Colorectal Cancer Screening Decision-Making: A Randomized Trial in the US and Australia	1	3	5	Whether or not to be screened for colorectal cancer, and, if yes, what screening test to use (4 unlabeled screening tests designed to simulate fecal occult blood testing, sigmoidoscopy, colonoscopy, or a radiological test like CT colonography)	1	Cancer - colorectal	No specific theory or framework mentioned in article.	After information section about adjuvant chemotherapy and trial.	Online	Rating scales	Rating and ranking	Rating and ranking	Rating a set of key attributes and then ranking the most important test attributes.	Participants were asked to rate (on a scale of 0 = not important at all to 5 = very important) a set of key testing attributes, then rank the three most important from the set.	1	4	Independently	Participants aged 50 to 75 years (online panel) at average risk (i.e. no personal or family history of CRC) for colorectal cancer.	305		One of three VCMs: balance sheet (implicit) vs rating and ranking (explicit) vs discrete choice experiment (explicit).	Participants were randomized to one of three VCM tasks: 1) balance sheet; 2) ranking and rating; 3) discrete choice experiment.	Different VCMs produced different results in terms of an individual's most important CRC screening test attribute but did not affect unlabeled test preference, post-task values clarity, or intent to be screened. These findings suggest that the VCM affects how respondents report what attributes of CRC screening they value most. Screening test attribute importance varied by VCM, but not by country
Brenner 2014 (3 of 3)	Brenner	alison.brenner@unc.edu	2013	Comparing 3 Values Clarification Methods for Colorectal Cancer Screening Decision-Making: A Randomized Trial in the US and Australia	1	3	5	Whether or not to be screened for colorectal cancer, and, if yes, what screening test to use (4 unlabeled screening tests designed to simulate fecal occult blood testing, sigmoidoscopy, colonoscopy, or a radiological test like CT colonography)	1	Cancer - colorectal	Discrete Choice Analysis	After information section about adjuvant chemotherapy and trial.	Online	Math based model	Discrete Choice Experiment	Discrete choice experiment	Conjoint (discrete choice).	Discrete Choice Experiment: respondents were asked to complete a series of choice tasks. In each task, they choose between hypothetical alternatives, each defined by a set of attributes and levels within these attributes. The levels of each attribute are varied systematically in a series of questions. Respondents choose the option that they prefer for each choice task/question.	1	4	Independently	Participants aged 50 to 75 years (online panel) at average risk (i.e. no personal or family history of CRC) for colorectal cancer.	306		One of three VCMs: balance sheet (implicit) vs rating and ranking (explicit) vs discrete choice experiment (explicit).	Participants were randomized to one of three VCM tasks: 1) balance sheet; 2) ranking and rating; 3) discrete choice experiment.	Different VCMs produced different results in terms of an individual's most important CRC screening test attribute but did not affect unlabeled test preference, post-task values clarity, or intent to be screened. These findings suggest that the VCM affects how respondents report what attributes of CRC screening they value most. Screening test attribute importance varied by VCM, but not by country
Clancy 1988	Clancy	n/a	1988	Guiding Individual Decisions: A Randomized, Controlled Trial of Decision Analysis	4	3	4	Choice between three options to manage risk of hepatitis B: (1) vaccination without antibody screening; (2) screening followed by vaccination if negative: and (3) waiting until recognized exposure, followed by administration of hepatitis B immune globulin.	1	Vaccination - hepatitis B	Decision analysis	After information about the availability of the vaccine and information about hepatitis B	Paper and computer (to generate the individualized decision analysis)	Math based model	Decision Analysis	Decision analysis	Structured probabilistic information plus individualized decision analysis.	Decision analysis: Step-by step instructions allowed each respondent to calculate a personal lifetime risk of hepatitis B infection, based on age, expected duration of practice, and blood exposure; provide a personal estimate for the probability of vaccine complications; and determine personal utilities for hepatitis outcomes and vaccine complications using a direct scaling method. Respondents received a letter that described the results of the analysis in nontechnical language. The letter indicated the physician's relative values for each of the three possible choices discussed in the informational material. The letter also described changes in relative value caused by varying the probability of hepatitis B infection, the probability of vaccine complications, the utility of vaccine complications, and any other values indicated	2	1	Independently and with the investigators	Resident and faculty physicians at the Hospital of the University of Pennsylvania.	1280		Not contacted (control) vs information only vs VCM + information	Randomized controlled trial in which resident and faculty physician was assigned to one of three study arms using a random numbers table: 1) Control (physicians were not contacted); 2) information only; 3) information plus individualized Decision Analysis.	Significantly more of the physicians offered the opportunity for individualized decision analysis were later screened or vaccinated compared to physicians in the other 2 groups.
deAchaval 2012	Suarez-Almazor	msalmazor@mdanderson.org	2012	Impact of Educational and Patient Decision Aids on Decisional Conflict Associated With Total Knee Arthroplasty	5	1	2	Whether or not to be treated for knee osteoarthritis (treatment options were either medication and therapy or total knee arthroplasty)	1	Knee osteoarthritis (OA)	Conjoint analysis	After watching/reading a video booklet DA	Computer-based	Math based model	Adaptive Conjoint Analysis	Adaptive conjoint analysis	Adaptive conjoint analysis (ACA).	Adaptive conjoint analysis (ACA): Patients were first presented with a list of 8 characteristics and were told to choose only 1 as being the most important thing to them "when thinking about knee replacement surgery." They then were led to a screen where they ranked each of the 7 other attributes on a scale from 1–10 ("not nearly as important" to "just as important") compared to the first chosen attribute. These rankings were used by the software to generate an initial estimate of each subject's values. Next, participants were presented with 2 treatment choices (described to be "exactly the same except for the differences [provided]") and asked to select their preference (weighted scale ranging from "strongly prefer left" to "strongly prefer right"). Each treatment option provided was described with the same 2 attributes at 2 different	1	1	Independently following instruction from the study coordinator	Patients with knee OA diagnosed with a radiograph.	208		Information only (control) vs DA only (video booklet) vs DA+VCM (videobooklet + ACA)	Randomized controlled trial with 3 arms: 1) educational booklet on OA management (control); 2) patient decision aid (video booklet) on OA management, and; 3) patient decision aid (video booklet) and adaptive conjoint analysis (ACA) tool.	Decisional conflict decreased among all patient groups receiving information about treatment options for OA. Those who received the control brochure had the smallest reduction in decisional conflict, while those who viewed the video booklet had the greatest reduction in decisional conflict. In other words, the audiovisual patient decision aid decreased decisional conflict more than printed material alone or the addition of a more complex computer-based ACA tool requiring more intense cognitive involvement and explicit value choices.
Epstein 2018	Epstein	epsteina@mskcc.org	2018	A Randomized Trial of Acceptability and Effects of Values-Based Advance Care Planning in Outpatient Oncology: Person-Centered Oncologic Care and Choices	5	2	Numerous	Personal preferences for end-of-life care: 1) CPR and mechanical ventilation are components of life-prolonging care aiming to prolong life and they usually take place in an intensive care unit; 2) limited care includes all measures including disease-directed treatments (such as chemotherapy), sometimes in the hospital, but not CPR or mechanical ventilation; and 3) comfort care prioritizes symptom management.	1	Cancer - gastrointestinal	Behavioral science theoretical models (e.g. Information-Motivation-Behavioral Skills Model)	After watching an informational care video	Verbal (interview)	List of concerns (interview)	List of Concerns	Discuss only	Interview (11 questions) focusing on goals, concerns and sources of support.	The 11 P-COCC values questions, previously validated and described in detail, focus on goals (e.g., experiences most important to live well at this time), concerns (e.g., fears or worries about the illness), and sources of support (e.g., in the face of serious challenges), and two of them specifically ask about goals and concerns related to the care goals video.	4	3	With a member of the research team	English-speaking patients aged 21 years or older with advanced gastrointestinal cancer.	99	151 were consented and randomized, 99 whom completed study	Usual care (no values interview or video viewing) vs VCM and video (values interview with care goals video) vs Video alone	Randomized controlled trial in which participants were randomized 2:2:1 by random permuted block to the P-COCC intervention (values interview with care goals video), video only, or usual care (no values interview or video viewing), respectively.	The values-based Advanced Care Planning intervention is acceptable but may increase distress in cancer outpatients. Further studies are investigating the underpinnings of these effects and ways to best support cancer patients in ACP
Feldman-Stewart 2006	Feldman-Stewart	deb.feldman-stewart@krcc.on.ca	2006	An explicit values clarification task: Development and validation	5	3	4	Choice between four main options for early stage prostate cancer (watchful waiting, surgery, external beam radiation and brachytherapy.)	2	Cancer - prostate	Behavioral science models (i.e. additive and additive-difference theoretical decision rules)	After information section about four treatment options.	Computer-based	Math based model	Decision Analysis	Decision analysis	Selection of attributes affecting the treatment decision.	Each participant was provided with the information about the disease and treatment options that we include in our decision aid. All groups saw the same information and it was presented in a table with attributes in the rows and treatment options in columns. Twenty attributes were presented and each attribute was described for those treated with each treatment. The participant selected each attribute (of either the treatments or of the disease) that was important to his decision. Bars were then presented for each of the identified attributes. Participants adjusted each bar, indicating what option that attribute "pushed" them toward and by how much. Participants then indicated their decision.	1	1	Independently	Male volunteers, at least 50 years old. Participants were asked to imagine that they had just been diagnosed with early-stage prostate cancer.	90		No VCM (control) vs VCM with summary vs VCM only	Randomized: 1) no VCM (control); 2) VCM with summary; 3) VCM without summary	Explicit VCM increased preparation for decision making and decreased decision regret. Decision conflict decreased in both arms.
Feldman-Stewart 2012	Feldman-Stewart	deb.feldman-stewart@krcc.on.ca	2012	The Impact of Explicit Values Clarification Exercises in a Patient Decision Aid Emerges after the Decision Is Actually Made: Evidence from a Randomized Controlled Trial	5	3	5+	Choice between more than five main options for early stage prostate cancer (Surgery, Brachytherapy, External beam radiation, Cryotherapy, No treatment for now, Others)	1	Cancer - prostate	Differentiation and Consolidation (Diff Con)	After information provided about the disease and treatment options	Computer-based	Math based model	Decision Analysis	Decision analysis	Selection of attributes affecting the treatment decision.	Bar-setting exercise: an explicit values clarification task designed to assist the integration of attributes relevant to the specific patient. In the decision aid, the attributes identified by the patient in the last listing exercise are brought forward to the integration exercise. Thus, in the integration task, the patient sets 1 bar for each of the identified attributes, and the bars are then averaged to identify the preferred option.	1	1	Independently	Newly diagnosed prostate cancer patients with low or intermediate risk early-stage disease (Stage T1 or T2, PSA<20, and Gleason<8), visiting the cancer clinic for their first consultation, and faced with a treatment decision.	156		DA (well-structured information) vs DA + VCM (well-structured information + Val Ex)	Randomized controlled study with 2 arms: 1) structured information only; 2) structured information plus VCM. Group assignment was done by computer at random with neither the clinician nor the patient knowing in advance which group the patient would be assigned to.	The results suggest that the values clarification exercises led to better preparation for decision making and to less regret. The impact, however, only emerged after the decision was made.
Fraenkel 2007	Fraenkel	liana.fraenkel@yale.edu	2007	Improving Informed Decision-Making for Patients with Knee Pain	5	2	5	Preferences for the following treatments: 1) pills (acetaminophen, anti-inflammatory drugs); 2) cream (capsaicin); 3) intra articular injections; 4) exercise, or; 5) a combination of exercise and medications.	1	Knee pain	Adaptive Conjoint Analysis (ACA)	After an information section on living with osteoarthritis.	Computer-based	Math based model	Adaptive Conjoint Analysis	Adaptive Conjoint Analysis	Participants first ranked different routes of administration, they then rated different alternatives, finally they rated a series of paired comparisons before being presented with a scale comparing the relative importance of their choices.	In the first series of questions, respondents were asked to rank different routes of administration. In the second, participants rated the importance of the difference between the best and worst alternative for each treatment characteristic. In the third series of questions respondents were asked to rate a series of paired-comparisons. Participants were subsequently given a handout illustrating the relative influence of each characteristic on their treatment preferences and a scale showing the relative ranking of the options.	1	1	Independently	Patients in Veterans Affairs Connecticut Healthcare System clinics, age at least 60 years old, self report of pain involving one or both knees on most days of the month, the ability to read and understand English, and the ability to perform a choice task.	87	87 randomized (of a total of 110)	DA vs VCM	Randomized: 1) only the information pamphlet (control); 2) only the VCM (Adaptive Conjoint Analysis task)	Patients randomized to perform this intervention had greater self-confidence in their abilities to participate in shared decision-making, felt more prepared to participate in decision-making, and had greater arthritis self-efficacy compared to the control group.
Frosch 2008	Frosch	dfrosch@mednet.ucla.edu	2008	Internet Patient Decision Support: A Randomized Controlled Trial Comparing Alternative Approaches for Men Considering Prostate Cancer Screening	1	1	2	Whether or not to be screened for prostate cancer	1	Cancer - prostate	No specific theory or framework mentioned in article.	After information provided about the disease and treatment options	Online	Math based model	Time tradeoff and visual analog rating	Time trade off and visual analog rating.	Chronic disease trajectory model including time–trade-off exercise and visual analog ratings.	Chronic disease trajectory model that activated patients to express utilities for outcomes associated with a prostate cancer life course by contrasting screening with no screening in its impact on quality of life and longevity. The intervention prompted men to complete a time–trade-off exercise and visual analog ratings of prostate cancer disease trajectories.	1	4	Independently	Men older than 50 years scheduled to be seen at the Health Appraisal Clinic of Kaiser Permanente.	611		Control vs DA vs VCM (chronic disease trajectory model) vs DA+VCM	Randomized 2x2 factorial controlled trial design with 4 arms, resulting in 4 groups: (1) traditional decision aid (TDA); (2) chronic disease trajectory model (DTM); (3) combined traditional decision aid and chronic disease trajectory model, and; (4) control group.	Participants assigned to the TDA group showed the highest prostate cancer knowledge scores and lowest decisional conflict scores, whereas the control group had the lowest prostate cancer knowledge scores. The TDA also appeared more effective than the DTM in improving prostate cancer knowledge and reducing decisional conflict. Men assigned to the control group did not show differential levels of concern about prostate cancer depending on what screening decision they made. By contrast,men assigned to the experimental interventions who chose not to screen indicated less concern about prostate cancer, suggesting better congruency between their values and their screening decisions than in the control group.
Garvelink 2014 (1 of 2)	Garvelink	m.m.garvelink@lumc.nl	2014	Values clarification in a decision aid about fertility preservation: does it add to information provision?	5	1	2	Whether or not to undergo fertility preserving procedures prior to cancer treatment	2	Reproductive health - female	No specific theory or framework mentioned in article	After information section about about fertility preservation for breast cancer patients	Computer-based	Rating	Rating Scales	Visual analog scales	Patients rate the importance of separate statements and indicate the extent to which they favor treatment options.	Each VCM consists of statements about the consequences of a FP option, for each of which patients are asked to indicate the extent to which they were considered a benefit or disadvantage. Patients indicated on two VAS scales a) whether the statement is considered to be an advantage or disadvantage to the FP option, and b) the importance of the statement. Additionally, patients have the option to add arguments and rate these as well. After rating the importance of the separate statements, the DA generates a summary that provides an overview of patients' answers in descending order from most important to least important (as indicated by the patient). Moreover, patients can indicate the extent to which they are in favor of the treatment options, and make a decision based on their own values. Patients are not provided with a clear-cut	1	1	Independently	Healthy women aged 18-36 years old.	151	140 with complete data	VCM- (DA with information only) vs VCM+ (DA with information + VCM)	Randomized controlled trial with 2 arms: 1) DA with information only; 2) DA with VCM.	Experiment 1 showed no difference in knowledge or Decisional Conflict between DAs with or without a VCM. Secondary analyses revealed less Decisional Conflict for women who used the VCM compared to those who did not use the VCM, but it was unlikely that the VCM had caused this difference, since there was no difference in DC between women who received information plus VCM and used the VCM and women who received information only.

Garvelink 2014 (2 of 2)	Garvelink	m.m.garvelink@lumc.nl	2014	Values clarification in a decision aid about fertility preservation: does it add to information provision?	5	1	2	Whether or not to undergo fertility preserving procedures prior to cancer treatment	2	Reproductive health - female	No specific theory or framework mentioned in article	After information section about about fertility preservation for breast cancer patients	Computer-based	Rating	Rating Scales	Visual analog scales	Patients rate the importance of separate statements and indicate the extent to which they favor treatment options.	Each VCM consists of statements about the consequences of a FP option, for each of which patients are asked to indicate the extent to which they were considered a benefit or disadvantage. Patients indicated on two VAS scales a) whether the statement is considered to be an advantage or disadvantage to the FP option, and b) the importance of the statement. Additionally, patients have the option to add arguments and rate these as well. After rating the importance of the separate statements, the DA generates a summary that provides an overview of patients' answers in descending order from most important to least important (as indicated by the patient). Moreover, patients can indicate the extent to which they are in favor of the treatment options, and make a decision based on their own values. Patients are not provided with a clear-cut	1	1	Independently	Healthy women aged 18-32 years old.	199	197 with complete data	VCM- (DA with information only) vs VCM+ (DA with information + VCM without referring to the VCM) vs VCM++ (DA with information + VCM with explicitly referring to the VCM)	Each VCM consists of statements about the consequences of a FP option, for each of which patients are asked to indicate the extent to which they were considered a benefit or disadvantage. Patients indicated on two VAS scales a) whether the statement is considered to be an advantage or disadvantage to the FP option, and b) the importance of the statement. Additionally, patients have the option to add arguments and rate these as well. After rating the importance of the separate statements, the DA generates a summary that provides an overview of patients' answers in descending order from most important to least important (as indicated by the patient). Moreover, patients can indicate the extent to which they are in favor of the treatment	Experiment 2 confirmed that there was no association between VCM-use and DC or knowledge, and showed that information seeking style affected DA use (number of pages viewed), but not VCM use. Personality traits were to some extent associated with aspects of DC. In both experiments there was a large knowledge increase of both DAs, indicating that the information in the DA is beneficial with regard to knowledge, especially for women who use the DA more thoroughly, highly conscientious women and women with more monitoring information seeking styles.
Hess 2015	Hess	lmhess@iupui.edu	2015	Preference Elicitation Tool for Abnormal Uterine Bleeding Treatment: A Randomized Controlled Trial	5	3	5+	Whether or not to be treated for abnormal uterine bleeding, and, if yes, which treatment to undertake (Prescription medication, Intrauterine device, Endometrial ablation, Hysterectomy, Others)	1	Reproductive health - female	Adaptive conjoint analysis (ACA)	n/a - not a DA	Computer-based	Math based model	Adaptive Conjoint Analysis	Adaptive conjoint analysis	Participants indicate their preferences across eight attributes: treatment efficacy; sexual function; medical care; cost; fertility; frequency of medication use; permanence; and recovery time.	Participants in the ACA group answered a series of preference-based questions to elicit their values across each of the eight treatment attributes (treatment efficacy; sexual function; medical care; cost; fertility; frequency of medication use; permanence; and recovery time) and through various combinations of those attributes. Immediately following completion of the ACA survey, the printed results were provided to the patient and the physician for use during the patient consult along with a guide to interpretation of the results.	1	1	Independently	Women aged 18 years or older with abnormal uterine bleeding who were potential candidates for either surgical or medical treatment.	374		No VCM (usual care) vs VCM (adaptive conjoint analysis)	Randomized controlled trial with 2 arms via a simple 1:1 randomization method using SPSS random number generation: 1) VCM (adaptive conjoint analysis); 2) usual counseling.	A preference elicitation tool at the initial consultation visit did not reduce decision regret or improve treatment satisfaction. There is a need for additional research to further understand the tool's potential role in promoting collaborative decision making, which may be particularly important among young women.
Hopkin 2019	Naci	h.naci@lse.ac.uk	2019	Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection	5	2	5	Preference for a statin (simvastatin, lovastatin, atorvastatin, pravastatin, rosuvastatin)	2	Cardiovascular disease - statin	Subjective expected utility theory (SEUT)	After information section (control charts)	Online	Math based model	Decision Analysis	Decision analysis	Ranking along two broad components: user preferences for different outcomes; performances of individual statins on these different outcomes.	Interactive web-based tool that synthesizes key findings from published network meta-analyses on the benefits and tolerability and harms of the five most commonly used cholesterol-lowering treatments, statins. The tool allows users to specify the importance of each benefit and harm outcome according to their own preferences, and this information is combined with information on the relative effects of the statins obtained from the network meta-analyses. The ranking is therefore based on two components: 1) user preferences for different outcomes and 2) performance of individual statins on these different outcomes. While the former is directly entered by the user by moving the cursor from ''Not important'' to ''Very important,'' the latter is obtained from published network meta-analyses. Network meta-analyses forming the basis of the tool	1	1	Independently	General adult US population sample recruited via MTurk.	349		DA with information (control bar charts) vs DA with VCM (interactive tool + control bar charts)	Randomized control trial with 2 arms: 1) DA only; 2) DA and VCM. Participants were randomized to either see the control charts only or to see the control charts followed by the interactive tool.	Our findings in this randomized controlled trial demonstrate that an interactive tool can have a positive effect on decisional conflict and preparation for decision making as well as have an impact on the reported rankings of different treatments. Participants in our study judged the content of the tool to be appropriate, clearly presented, and balanced. The tool also had high acceptability: the vast majority of participants reported that they would be likely or very likely to use it if it was available. Individuals using the interactive tool reported considerably lower levels of decisional conflict and may have had higher levels of preparation for decision making, albeit with some lack of precision on this latter outcome.
Hutyra 2019	Hutyra	carolyn.hutyra@duke.edu	2019	Efficacy of a Preference-Based Decision Tool on Treatment Decisions for a First-Time Anterior Shoulder Dislocation: A Randomized Controlled Trial of At-Risk Patients	5	2	2	Preference for operative or nonoperative treatment for first-time anterior shoulder dislocation	2	Orthopedics - first-time anterior shoulder dislocations (FTASD)	Micro-economic utility theory; Adaptive conjoint analysis (ACA)	After information section	Computer-based	Math based model	Adaptive Conjoint Analysis	Adaptive conjoint analysis	Rating preferences for various processes and outcomes of treatment, and displayed a graph of attribute importance values summed to 100%.	The electronic instrument provided information on FTASD, introduced treatment attributes, guided respondents through an ACA exercise to measure preferences for various processes and outcomes of treatment, and displayed a personalized graph of attribute importance values summed to 100%. The ACA exercise attributes were based on clinical evidence and included 1) limited arm movement, 2) avoidance of high-risk activities, 3) risk of recurrent dislocation, and 4) out-of-pocket cost. The ACA design consisted of 8 tradeoff questions ranked on a 9-point Likert-type scale that provided varying combinations of attribute levels for each choice task. Each attribute was displayed 6 to 7 times throughout the exercise. The number of attributes per choice task increased incrementally from 2 to 4 as the ACA exercise progressed, and the order of	1	1	Independently	People between 18 and 35 years of age at risk for experiencing a first-time anterior shoulder dislocation (orthopedic patients with shoulder injuries, including but not limited to shoulder dislocations and instability).	200		Text-based DA with information only (control) vs interactive DA + VCM (adaptive conjoint analysis + text-based decision aid)	Randomized controlled trial with 2 arms: 1) text-based DA; 2) interactive DA with VCM.	An interactive, preference-based decision tool for treatment of FTASD affects patient decision making by guiding respondents toward treatment decisions that align more closely with evidence-based recommendations in the absence of a consultation with an orthopedic provider compared with a standard-of-care control tool. Additional study is needed to evaluate the long-term effects of this tool on treatment outcomes, patient adherence,and satisfaction.
Jayadevappa 2015	Jayadevappa	jravi@mail.med.upenn.edu	2015	Treatment preference and patient centered prostate cancer care: Design and rationale	5	2	6	Choice between six main options for early stage prostate cancer (Active surveillance; Watchful waiting; Radical prostatectomy, including robotic-assisted laparoscopic prostatectomy; External beam radiation therapy; Brachytherapy; Proton therapy)	1	Cancer - prostate	Preference assessment theory	n/a - not a DA	Computer-based	Math based model	Adaptive Conjoint Analysis	Adaptive conjoint analysis	Selection of features that are most important.	In the first part, brief overview of the instrument is provided. In the second part, the participants ranked (ranging from 'not important' to 'extremely important') the attributes of various treatments. In the third part, choice scenarios consisting of combinations of attributes are presented based on the ranking of the attributes. The participants are asked to select the combination that they preferred most (five choices ranged from 'strongly prefer treatment A' to 'strongly prefer treatment B'). At the end of the task, a graph and a list of the top five attributes most preferred by the participant is generated. The participants are offered an option to have a printout of this list and graph and share it with their providers. On average, this instrument required 30–40 min to complete. The participant could complete the instrument on a laptop in the practice or could choose	1	1	Independently	Patients: (1) treated for prostate cancer; (2) aged ≥18 years; (3) newly diagnosed with localized prostate cancer (diagnosed within last one year and haven't received curative intent treatment for prostate cancer); (4) low risk (PSA ≤10 ng/ml, and Gleason ≤6, and stage T1c–T2a), intermediate risk (PSA N10–≤20 ng/ml, or Gleason 7, or stage T2b), and high risk (PSA N 20 ng/ml, or Gleason score 8–10, or stage T2c) group.	743		Usual care vs VCM	Randomized controlled trial with 2 arms: 1) VCM; 2) usual care.	Our patient-centered PreProCare intervention improved satisfaction with care, satisfaction with decision, reduced regrets, and aligned treatment choice with risk category. The majority of our participants had a high income, with implications for generalizability.
Kennedy 2002	Kennedy	andrew.kennedy@brunel.ac.uk	2002	Effects of Decision Aids for Menorrhagia on Treatment Choices, Health Outcomes, and Costs. A Randomized Controlled Trial	5	2	4 or more	Choice between treatment options for menorrhagia (advice and reassurance, addressing possible iatrogenic causes, drug therapy, or surgery such as hysterectomy or endometrial destruction)	1	Reproductive health - female - menorrhagia	No specific theory or framework mentioned in article.	After information (DA: booklet and video)	Verbal (structured interview) with paper (booklet encourages women to record their preferences)	List of concerns (interview)	List of Concerns	Discuss only	Structured interview to help patients clarify and articulate their preferences and provide additional information.	The interview attempted to explicitly clarify values and elicit treatment preferences. The purpose of the interview was to help patients clarify and articulate their preferences, and to give them the chance to provide information that they might not have the opportunity or inclination to reveal to their physician.	4	1	With a research nurse	Women with uncomplicated menorrhagia.	894		Standard practice (control) vs VCM (interview + video/booklet) vs. No VCM (video/booklet)	Randomized with 3 arms: 1) a standard practice control group with no intervention; 2) an information group, which received the booklet and videotape, sent to their homes 6 weeks before their consultation; and 3) an interview group, which received the same materials as the information group and who underwent the interview before their consultation.	Neither intervention had an effect on health status. Providing women with information alone did not affect treatment choices; however, the addition of an interview to clarify values and elicit preferences had a significant effect on women's management and resulted in reduced costs.
Kuppermann 2014	Kuppermann	kuppermannm@obgyn.ucsf.edu	2014	Effect of Enhanced Information, Values Clarification, and Removal of Financial Barriers on Use of Prenatal Genetic Testing. A Randomized Clinical Trial	2	3	Numerous	Three options: (1) whether or not to have any testing; (2) if testing is desired, whether to start with screening or with invasive diagnostic testing; and (3) which specific screening and/or diagnostic test(s) to undergo.	1	Prenatal screening	No specific theory or framework mentioned in article.	After information section (general information about prenatal testing and the role of values and preferences in prenatal testing decisions, etc.)	Computer-based	Rating	Rating Scales	Likert scales	The user is then asked to complete values clarification questions focusing on 3 decisions: (1) whether or not to have any testing; (2) if testing is desired, whether to start with screening or with invasive diagnostic testing; and (3) which specific screening and/or diagnostic test(s) to undergo. Afterwards, the user can receive graphic highlights of the testing strategy that is most consistent with the her responses, as well as click to obtain detailed information on the features of that strategy or any of the other strategies.	The user is presented with her personalized, age-related chances of carrying a fetus with aneuploidy. She is then asked to complete values clarification questions focusing on 3 decisions: (1) whether or not to have any testing; (2) if testing is desired, whether to start with screening or with invasive diagnostic testing; and (3) which specific screening and/or diagnostic test(s) to undergo. Afterwards, the user can receive graphic highlights of the testing strategy that is most consistent with the her responses, as well as click to obtain detailed information on the features of that strategy or any of the other strategies. The program concludes by encouraging the user to discuss questions with her clinician, while emphasizing that the testing strategy to undergo is her choice.	1	1	Independently	English- or Spanish-speaking pregnant women being less than or equal to 20 weeks of gestation with a singleton or twins who had not yet undergone screening or diagnostic testing for fetal aneuploidy in the current pregnancy.	710		Information only (control) vs VCM + Information (information on both screening and diagnostic tests)	Randomized controlled trial with 2 arms: 1) control group; 2) DA and VCM group.	Full implementation of prenatal testing guidelines, using a computerized, interactive decision-support guide in the absence of financial barriers to testing, resulted in less prenatal test use and more informed choices.
Lerman 1997	Lerman	n/a. New email: clerman@usc.edu	1997	Controlled Trial of Pretest Education Approaches to Enhance Informed Decision-Making for BRCA1 Gene Testing	3	1	2	Whether or not to provide a blood sample for BRCA1 testing in the future.	1	Cancer - breast	Behavioral models of decision-making	After information education on patterns of inheritance, benefits, limitations and risks of testing, and limitations of options.	Verbal (non-directive counseling using a semi-structured protocol)	List of concerns (semi-structured interview)	List of concerns	Discuss only	After the education section, participants receiving nondirective counseling where five sets of issues were discussed using a semi structured protocol.	The following specific issues were addressed using a semi-structured protocol: (a) experience with cancer in the family, including psychosocial impact; (b) anticipated impact of positive or negative BRCA1 test results, including impact on psychological and functional status, personal relationships, and medical outcomes; (c) anticipated outcomes of deciding not to be tested; (d) perceived coping resources and skills to adapt to different testing outcomes; and (e) intentions regarding communication of test results to family, friends, and others.	2	4	With trained oncology nurses or a genetic counselor supervisor	Women aged 18-75 years who had had at least one first-degree relative with breast and/or ovarian cancer.	400	122 randomized to education and counselling	No VCM (waiting-list) vs DA (educational approach) vs DA + VCM	Randomized: 1) a waiting-list control; 2) education only; 3) education and counseling	As predicted, compared with the control condition, the educational approach led to statistically significant increases in knowledge and small, but statistically significant, decreases in perceived personal risk of having a BRCA1 mutation.The results also showed that the counseling approach, but not the educational approach, was superior to the control condition in increasing the perceived importance of the limitations and risks of BRCA1 testing and in decreasing the perceived importance of the benefits of BRCA1 testing. However, neither the educational nor the counseling approach produced statistically significant changes in intentions to have BRCA1 testing in this population. Both before and after counseling,
Matheis-Kraft 1997	Matheis-Kraft	n/a	1997	Influence of a values discussion on congruence between elderly women and their families on critical health care decisions	5	2	Numerous	Preferences for care in case of decisional incapacity	3	Advanced care planning - decisional incapacity	Theory of surrogate decision making	n/a - not a DA	Verbal	List of concerns (interview)	List of Concerns	Ranking, and list and discuss	Prioritization: Pick your top N from a list (step 1) and discuss your personal values (step 2).	Each woman was asked to choose from the list of value indicators those most influential to her medical decision making. The women could also add to the list, but no one did. The women were prompted to discuss what influence each item would have on their medical decisions and why this would be important to them. The researcher asked the women to elaborate or give example to clarify for the proxies the importance of the value indicator.	4	3	With likely surrogate decision maker	Women over age 70 and having at least one family member or friend who could participate as a proxy.	60		No VCM (no discussion) vs VCM (discussion with a proxy)	Randomized: 1) control group where the women and proxy independently made medical decisions without a values discussion; 2) experimental group where women had a discussion with the proxy about their values prior to the two independently deciding on medical interventions for the older woman.	VCM with education resulted in increased perceptions of risks and limitations of BRCA1 testing, but knowledge was no better than education alone. Perceived personal risk decreased more with education alone, and neither VCM and education nor education alone influenced perceptions of benefits of BRCA1 testing, decision intentions, or decisions.
Montgomery 2003	Montgomery	alan.a.montgomery@bristol.ac.uk	2003	A factorial randomised controlled trial of decision analysis and an information video plus leaflet for newly diagnosed hypertensive patients	5	1	2	Whether or not to start drug therapy for hypertension	1	Cardiovascular disease - hypertension	VCM is implied to be based on expected utility theory (decision analysis).	Before possible information (participants randomized to receive video and leaflet after decision analysis or not)	Computer-based	Math based model	Decision Analysis	Decision analysis	Patients' utilities were assessed using a computerised self-completed interview with minimal input from the researcher. Individual absolute cardiovascular risk was calculated and combined with utilities using decision analysis software. The purpose of the decision tree and the individual nature of its components were explained to participants. At the end of the intervention, participants were given a printed sheet detailing their cardiovascular risk factors and summarising the decision analysis; that is, whether the 'optimal' decision determined by maximised expected utility would be to accept or decline pharmacological treatment.	Decision analysis is a technique to aid decision making when uncertainty exists over the balance between benefits and risks of treatment.The technique employed here was a simple decision tree, constructed to include likely outcomes of treatment options. These outcome health states were rated by patients to give utility values, represented on a quantitative scale between 0 and 1. The decision tree for hypertension used in the present study, sources of probability data, and descriptions of the standard gamble method of assessing patient utilities have been reported previously. Patients' utilities were assessed using a computerised self-completed interview with minimal input from the researcher. Individual absolute cardiovascular risk was calculated and combined with utilities using decision analysis software. The	1	1	With minimal assistance from research assistant	Adults aged 30-80 years with newly diagnosed hypertension.	217		No VCM (usual care; control) vs VCM + education (decision analysis + video/leaflet) vs VCM only (decision analysis) vs education only (video/leaflet)	Randomized 2 x 2 factorial design. Patients were first allocated to 'decision analysis' or 'no decision analysis', minimising by age and sex, and stratified according to practice. Patients were further randomised to 'video/leaflet' or 'no video/leaflet' using the same procedure. Randomized: 1) decision analysis + video/leaflet; 2) decision analysis only; 3) video/leaflet only; 4) usual care (control).	This study has demonstrated that both relatively complex (decision analysis) and simple (information video/leaflet) decision aids are effective in reducing decisional conflict among newly diagnosed hypertensive patients. Decision analysis had a greater effect on total decisional conflict than the video/leaflet and this was further reflected in each of the decisional conflict subscales. The antagonistic interaction between the two interventions suggests there may be a ceiling to the amount of information and assistance that patients benefit from, in terms of decisional conflict and knowledge.
Montgomery 2007	Montgomery	alan.a.montgomery@bristol.ac.uk	2007	Two Decision Aids for Mode of Delivery among Women with Previous Caesarean Section: Randomised Controlled Trial	5	2	3	Choice of planned mode of delivery, i.e. planned vaginal birth, elective caesarean section, and emergency caesarean section.	1	Reproductive - maternal health - mode of delivery	Utility theory	After information about the outcomes associated with planned vaginal delivery, elective caesarean section, and emergency caesarean section	Computer-based	Math based model	Decision Analysis	Decision analysis	Women were given information about the outcomes associated with each form of delivery. Then women were required to consider the value they attached to possible outcomes by rating each on a visual analogue scale from 0 to 100.	Women were given information about the outcomes associated with planned vaginal delivery, elective caesarean section, and emergency caesarean section. This comprised descriptions, but not explicit probabilities, of outcomes for both mother and baby. Secondly, women were required to consider the value they attached to possible outcomes by rating each on a visual analogue scale from 0 to 100. Though these ratings are not strictly equivalent to utility values, we considered this to be a pragmatic method of assessment and the information produced to be sufficient for this study. We combined the values with the probabilities of each outcome in a decision tree to produce a recommended "preferred option" based on maximised expected utility. Women received a computer printout of the outcome of the decision analysis and	1	1	With minimal assistance from research assistant	English-speaking pregnant women with one previous lower segment caesarean section, no current obstetric problems, and delivery expected at ≥37 weeks.	742		No VCM (usual care) vs VCM (decision analysis) vs Information only	Randomized controlled trial with 3 arms: 1) VCM (decision analysis); 2) Information programme; 3) usual care.	Computer based decision aids can reduce decisional conflict among pregnant women with one previous caesarean section. Both decision aids in our study were associated with greater knowledge and less anxiety compared with usual care. The intervention based on decision analysis was associated with a higher proportion of women achieving a vaginal birth.
Myers 2003	Myers	ron.myers@mail.tju.edu	2003	Value Based Decision-Making in Prostate Cancer Early Detection	1	1	2	Whether or not to be screened for prostate cancer (DRE and/or PSA)	1	Cancer - prostate	Analytical Health Process methods	After DA (information)	Verbal with paper (booklet reviewed with a health educator)	Math based model	Analytical Hierarchy Process	Analytical hierarchy	The health educator prompts the patient to identify decision factors [...] Each participant was then asked to identify and rank the three most important factors and make pairwise comparisons of the relative importance of those three factors. Following Analytical Hierarchy Process methods, the health educator guided the men to assign values to the decision factors and used assigned values to calculate the participant's screening preference score.	Counseling protocol that was designed to help participants to clarify their preference concerning whether or not to have a prostate-cancer screening exam. The protocol focused on identifying factors that might affect the individual's preferences (decision factors) and by generating a decision preference score based on the most salient decision scores. The health educator prompts the patient to identify decision factors [...] Each participant was then asked to identify and rank the three most important factors and make pairwise comparisons of the relative importance of those three factors. Following Analytical Hierarchy Process methods, the health educator guided the men to assign values to the decision factors and used assigned values to calculate the participant's screening preference score.	1	1	With assistance from a health educator	Men aged 50 to 69 who were patients at Jefferson Internal Medicine Associates and with no personal history of prostate cancer/benign prostate hyperplasia and who had not had a prostate biopsy or transrectal ultrasound procedure.	199		No VCM (DA only) vs VCM (DA + decision counseling session)	Randomized controlled trial with 2 arms: 1) standard intervention group; 2) enhanced intervention group.	The VCM group had lower rates of screening than the standard intervention group. Both groups had similar PSA testing rates. There were race/ethnicity differences in screening utilization , specifically African American men increased their PSA screening utilization while White men decreased their screening utilization.

Myers 2005	Myers	ron.myers@mail.tju.edu	2005	Preparing African-American Men in Community Primary Care Practices to Decide Whether or Not to Have Prostate Cancer Screening	1	3	3	Whether or not to be screened for prostate cancer, if yes: 1) complete screening (i.e digital rectal exam (DRE) and prostate specific antigen (PSA) testing, or 2) partial screening (at least DRE)	1	Cancer - prostate	No specific theory or framework mentioned in article	After information booklet on prostate cancer	Verbal with paper (booklet reviewed with a health educator)	Math based model	Analytical Hierarchy Process	Analytical hierarchy	Decision education is a method that was developed to enable individuals to consider available information about a healthcare decision, along with personal values related to available alternatives, in order to clarify personal preference and, as a result, make an informed decision.	In addition to receiving the booklet, men in the EI group were contacted via telephone by a trained health educator one month after booklet mailing to arrange for a decision education session about prostate cancer screening. Decision education is a method that was developed to enable individuals to consider available information about a healthcare decision, along with personal values related to available alternatives, in order to clarify personal preference and, as a result, make an informed decision. Briefly, the decision education session initially involved eliciting the major decision factors influencing the participant's decision to have or not to have screening. The participant then identified his top three decision factors, reported the strength of their influence (how strongly each one influenced him either for or against screening), and	1	1	With assistance from a health educator	African-American men from three primary care practices who were 40-69 years of age and had no history of prostate cancer.	242		No VCM (standard intervention = booklet only) vs VCM (enhanced intervention = booklet + counseling session)	Randomized with 2 arms: 1) standard intervention (i.e. information only); 2) enhanced intervention (i.e. information and decision education session).	Multivariable analyses showed that being in the enhanced intervention group and primary care practice were significant predictors of complete or partial screening (OR=3.9 and OR=5.64, respectively)
O'Connor 1999	O'Connor	aoconnor@LRI.ca	1999	The effects of an `explicit' values clarification exercise in a woman's decision aid regarding postmenopausal hormone therapy	4	1	2	Whether or not to take hormone replacement therapy after menopause	1	Reproductive health - female - menopause (related complications)	Unclear if specific theory or framework were used for values clarification development	After information (booklet and audiotape) about chemotherapy risks and benefits.	Paper (DA also has audiotape)	Pros and cons	Pros and Cons	With weighting	Women [completed] their own weigh-scale exercise which involved: (1) reviewing each benefit and risk box situated in the weigh-scale; (2) personalizing the boxes labelled `other positives' and `other negatives' by inserting other reasons one would take or not take HRT in addition to those listed; (3) valuing the personal importance of each bene®t and risk by shading the boxes in the scale (completely shaded 'very important to me; partially shaded 'quite or slightly important; no shading 'not at all important to me); and (4) indicating her predisposition or 'leaning' toward taking HRT using a 15-point scale situated under the weigh-scale anchored by `yes HRT' and `no HRT' with `unsure' situated at the midpoint.	There were three steps in the exercise. Firstly, a woman was provided with an overview of the exercise. Secondly, examples of how other women had completed the weigh-scale exercise were provided: one who was considering accepting HRT; one who was considering declining HRT; and two who were unsure. This segment re enforced the steps of the exercise and helped the women: to understand how values influence decisions; to understand that decisions do vary and that there is no right or wrong answer; and to identify from the sample value profiles which ones corresponded to their own. Thirdly, women were guided in completing their own weigh-scale exercise which involved: (1) reviewing each benefit and risk box situated in the weigh-scale; (2) personalizing the boxes labelled `other positives' and `other negatives' by inserting other reasons one would	2	3	Independently	Women aged 50-69 (post-menopausal) who had never used hormone therapy.	201		No explicit VCM vs Explicit VCM	Participants were randomized to use either: 1) a decision aid without the values clarification exercise; or 2) a decision aid with the explicit values clarification exercise using a graphic weigh-scale.	There were no statistically significant differences between interventions in perceived clarity of values and overall congruence between values and choices. Amongst those choosing HRT, there was a trend in those exposed to the graphic weigh-scale exercise to have better congruence between values and choices compared to implicit values clarification (P = 0.06).
Paquin 2018	Paquin	rpaquin@rti.org	2018	A behavior-theoretic evaluation of values clarification on parental beliefs and intentions toward genomic sequencing for newborns	3	2	2	Whether or not to use genomic sequencing to identify genetic variants in one's child	2	Prenatal screening	Reasoned action framework	After information (DA) about newborn screening, etc.	Online	Pros and cons	Pros and Cons	With binary	Values clarification exercise in which parents sort five reasons for and five reasons against having genomic sequencing for their child by importance. Parents completing the decision aid are also given the opportunity to add and sort any additional reasons that were important to their decision making. This task is followed by five questions to further clarify values.	The information section of the DA is followed by a values clarification exercise in which parents sort five reasons for and five reasons against having genomic sequencing for their child by importance. These reasons for and against having genomic sequencing were developed based on input from couples who were pregnant or had recently given birth (Fitzgerald et al., 2016; Moultrie et al., 2016), suggesting that they represent broadly salient, or accessible, beliefs about having genomic sequencing. Parents completing the decision aid are also given the opportunity to add and sort any additional reasons that were important to their decision making. This task is followed by five questions to further clarify values.	2	3	Independently	Women and men ages 18-44 who were pregnant or whose partner was pregnant or planning to become pregnant in the next 2 years.	1000		DA only vs VCM + DA	Randomized: 1) DA only (educational information); 2) DA and VCM (educational information followed by a values clarification exercise).	Participants who completed the decision aid with the values clarification exercise agreed less strongly with four of the five statements against sequencing compared to participants who viewed the education-only decision aid. The groups did not differ on agreement with reasons in support of sequencing. Agreement with four of five reasons against genomic sequencing was negatively associated with intentions to have their newborn sequenced, whereas agreement with all five reasons in support of sequencing were positively associated with intentions.
Peinado 2020	Peinado	speinado@rti.org	2020	Values Clarification and Parental Decision Making About Newborn Genomic Sequencing	3	1	2	Whether or not to use genomic sequencing to identify treatable conditions	2	Newborn screening	Human information processing	After DA (information)	Online	Pros and cons	Pros and Cons	With binary	A values clarification exercise in which parents sort five reasons for and five reasons against having genomic sequencing for their child by importance.	The information section of the DA is followed by a values clarification exercise in which parents sort five reasons for and five reasons against having genomic sequencing for their child by importance. These reasons for and against pursuing genomic sequencing were developed based on in-depth interviews with a diverse sample of 33 couples who were either pregnant or had recently given birth. The reasons parents gave in support of and against newborn genomic sequencing were reviewed by clinicians for medical accuracy —for example, to ensure they did not convey misunderstanding of the testing process or the implications of the results of testing(Fitzgerald et al., 2016; Moultrie et al., 2019). The values clarification exercise was restricted to five reasons in support of and five reasons against genomic sequencing due to	1	1	Independently	Women and men ages 18 to 44 years (Qualtrics sample) who were either currently pregnant or had a spouse or partner who was pregnant, were actively trying to get pregnant, or were contemplating or preparing for pregnancy within the next two years.	1000		DA only vs DA + VCM	Randomized: 1) DA only (educational information); 2) DA and VCM (educational information followed by a values clarification exercise).	Participants who completed a values clarification exercise in addition to viewing educational content reported less decision regret than those who were only exposed to the educational content. Participants who completed a values clarification exercise in addition to viewing educational content were clearer about their personal values. There was a significant interaction effect on decisional conflict from exposure to the values clarification exercise by health literacy. Participants in the values clarification condition reported greater values clarity and this, in turn, was associated with a greater intention to have one's child tested.
Pignone 2012 (1 of 2)	Pignone	pignone@med.unc.edu	2011	Conjoint Analysis Versus Rating and Ranking for Values Elicitation and Clarification in Colorectal Cancer Screening	1	3	5	Whether or not to be screened for colorectal cancer, and, if yes, what screening test to use (4 unlabeled screening tests designed to simulate fecal occult blood testing, sigmoidoscopy, colonoscopy, or a radiological test like CT colonography)	2	Cancer - colorectal	Conjoint analysis	n/a - not a DA	Computer-based	Math based model	Discrete Choice Experiment	Discrete choice experiment	Discrete choice task: For each task, the participant was asked to choose between options 1 and 2 or state that they had no preference between the two.	Conjoint task: Each choice task involved a comparison of two hypothetical options ("1" and "2") made up of the six attributes with different combinations of levels. For each task, the participant was asked to choose between options 1 and 2 or state that they had no preference between the two.	1	4	Independently	Adults 48-75 at average risk for colon cancer (no personal or immediate family history of colon cancer, polyps or inflammatory bowel disease).	104	54 (of a total of 104)	VCM with explicit tradeoffs (discrete choice) vs. VCM without explicit tradeoffs (rating and ranking)	Randomized: 1) Conjoint: discrete choice VCM; 2) Rating and ranking VCM.	Different types of VCM led to different patterns of indirect responses about which attribute is most important, but did not significantly affect direct responses, nor were there any observed differences on perceived clarity of values, intent to be screened, or choice of screening test.
Pignone 2012 (2 of 2)	Pignone	pignone@med.unc.edu	2011	Conjoint Analysis Versus Rating and Ranking for Values Elicitation and Clarification in Colorectal Cancer Screening	1	3	5	Whether or not to be screened for colorectal cancer, and, if yes, what screening test to use (4 unlabeled screening tests designed to simulate fecal occult blood testing, sigmoidoscopy, colonoscopy, or a radiological test like CT colonography)	2	Cancer - colorectal	No specific theory or framework mentioned in article.	n/a - not a DA	Paper	Prioritization exercise	Rating and Ranking	Rating and ranking	Rating scales and Prioritization: ranking.	Rating and Ranking Test: The rating exercise asked participants to rate, on a Likert scale of 1–6, the importance of each attribute (1 = not important; 6 = very important). The ranking task then asked the respondent to rank the three most important of the six attributes.	1	4	Independently	Adults 48-75 at average risk for colon cancer (no personal or immediate family history of colon cancer, polyps or inflammatory bowel disease).	104	60 (of a total of 104)	VCM with explicit tradeoffs (discrete choice) vs. VCM without explicit tradeoffs (rating and ranking)	Randomized: 1) Conjoint: discrete choice VCM; 2) Rating and ranking VCM.	Different types of VCM led to different patterns of indirect responses about which attribute is most important, but did not significantly affect direct responses, nor were there any observed differences on perceived clarity of values, intent to be screened, or choice of screening test.
Pignone 2013 (2 of 3)	Pignone	Michael_Pignone@med.unc.edu	2013	Comparing three techniques for eliciting patient values for decision making about prostate specific antigen screening: a randomized controlled trial	1	1	2	Whether or not to be screened for prostate cancer.	3	Cancer - prostate	No specific theory or framework mentioned in article.	After information (not clear if it's a DA) about prostate cancer and PSA screening	Online	Prioritization exercise	Rating and Ranking	Rating and ranking	Rating and ranking Task.	Rating and Ranking Task: The rating and ranking task asked participants to rate (on a scale of 0= not important at all to 5 = very important) and then rank the three most important screening test attributes from sets of the key attributes.	1	4	Independently	Average risk (i.e with no personal or family history of prostate cancer) men aged 50-70 (members of an online survey panel).	911	355 allocated (307 completed exercise)	VCM with explicit tradeoffs (discrete choice) vs. VCM without explicit tradeoffs (rating and ranking) vs VCM with implicit explicit tradeoffs (balance sheet)	Randomized: 1) implicit VCM (a balance sheet of key test attributes); 2) rating and ranking VCM; 3) conjoint analysis VCM (discrete choice experiment).	Different values clarification methods produce different patterns of attribute importance and different preferences for screening when presented with an unlabelled choice.
Pignone 2013 (3 of 3)	Pignone	Michael_Pignone@med.unc.edu	2013	Comparing three techniques for eliciting patient values for decision making about prostate specific antigen screening: a randomized controlled trial	1	1	2	Whether or not to be screened for prostate cancer.	3	Cancer - prostate	No specific theory or framework mentioned in article.	After information (not clear if it's a DA) about prostate cancer and PSA screening	Online	Math based model	Discrete Choice Experiment	Discrete choice experiment	Discrete choice experiment task.	Discrete choice experiment task: In discrete choice experiments (also known as choice-based conjoint analysis), respondents are asked to choose between hypothetical alternatives defined by a set of attributes. Respondents choose the option that they prefer for each question. People are assumed to choose the option that is most preferred, or has the highest "value" or "utility." From these choices, a mathematical function is estimated which describes numerically the value that respondents attach to different choice options. Each task included an active screening option and a fixed "no screening" option.	1	4	Independently	Average risk (i.e with no personal or family history of prostate cancer) men aged 50-70 (members of an online survey panel).	911	357 allocated (302 completed exercise)	VCM with explicit tradeoffs (discrete choice) vs. VCM without explicit tradeoffs (rating and ranking) vs VCM with implicit explicit tradeoffs (balance sheet)	Randomized: 1) implicit VCM (a balance sheet of key test attributes); 2) rating and ranking VCM; 3) conjoint analysis VCM (discrete choice experiment).	Different values clarification methods produce different patterns of attribute importance and different preferences for screening when presented with an unlabelled choice.
Sheridan 2010	Sheridan	sls593@med.unc.edu	2010	Effect of Adding a Values Clarification Exercise to a Decision Aid on Heart Disease Prevention: A Randomized Trial	4	3	5	Whether or not to initiate behaviours to prevent coronary heart disease (CHD), and, if so, which behaviours (aspirin, blood pressure medicine, cholesterol medicine, and/or smoking cessation)	2	Cardiovascular disease - coronary heart disease (CHD)	No specific theory or framework mentioned in article.	After information about four options to prevent CHD	Online	Prioritization exercise	Ranking and rating	Ranking and rating	Ranking and rating exercise, at the end of the exercise participants viewed a summary table of their answers.	Ranking and rating exercise: Values in our ranking and rating exercise were decisional attributes common to each of the treatment options presented in the decision aid (benefit for other medical conditions, side effects, degree of difficulty for most people, cost, and effect on others). These attributes were a subset of decisional attributes identified as relevant to participants in formative research 9 and were chosen for their differences across treatment options. During the values clarification exercise, participants first ranked the decisional attributes according to their individual importance to their decision making. They then rated whether each attribute related to their personal decision options; rating proceeded in the order of the previously ranked decisional attributes. At the end of the exercise, participants viewed	1	3	Independently	Men (registry participants) aged 45-80 with no prior history of cardiovascular disease.	137		DA only vs DA + VCM	Randomized: 1) DA; 2) DA with explicit VCM.	Adding a ranking and rating exercise to a heart disease prevention decision aid did not improve participants' decisional conflict, intent to reduce their CHD risk, sense of values concordance, or self-efficacy for risk reduction. It also did not improve process measures for the decision. Both our DA and our DA + VC interventions reduced decisional conflict and resulted in perceptions of decisions consistent with personal values and self-efficacy for CHD risk reduction. Neither had an effect on intent to reduce CHD risk, which was high at baseline and remained essentially unchanged in this study
Shirk 2017	Shirk	jshirk@mednet.ucla.edu	2017	Does Patient Preference Measurement in Decision Aids Improve Decisional Conflict? A Randomized Trial in Men with Prostate Cancer	5	2	3	Choice between three main options for incident localized prostate cancer (Active surveillance, radiotherapy, and surgery for prostate cancer)	1	Cancer - prostate	Ottawa decision support framework; Adaptive best-worst conjoint (ABC) approach	After an information brochure on the disease, treatment choices, and possible results	Computer-based	Math based model	Best-Worst Scaling	Best-worst scaling	Discrete choice application.	Non-proprietary discrete choice application to measure preferences for these treatment attributes (i.e. impact on sexual function, risk of urinary incontinence, risk of overactive bowel, impact on survival, treatment-related bodily violation/need for incision, whether ''important others'' approved of a decision, and whether the treatment made the patient feel he was ''taking action.''). The application uses 16 full-profile health states (stimuli). Each stimuli specifies levels for each of the seven attributes. ABC's best-worst algorithm is based on reconstructing a rank order for the 16 full-profile stimuli using patient responses on a series of choice tasks. In the application, patients were presented with sets of four full-profile health states and asked to identify their most preferred and least preferred health state. The application	1	1	Independently prior to consultation with physician	Men with incident localized prostate cancer at 3 Los Angeles clinics.	122		Pamphlet only (control) vs VCM + Pamphlet (intervention)	Randomized into one of two groups: 1) the control arm which received education via a printed educational brochure; 2) the intervention arm which received the educational brochure followed by preference assessment using a software program that used discrete-choice experiments to measure preferences for key outcomes.	Preference assessment prior to decision making reduced decisional conflict in men above and beyond improvements seen with high-quality patient education alone.
Witteman 2015	Witteman	holly.witteman@fmed.ulaval.ca	2015	Risk Communication, Values Clarification, and Vaccination Decisions	4	1	2	Whether or not to have their children vaccinated against influenza	1	Immunization - influenza	No specific theory or framework mentioned in article.	After information section on influenza	Computer-based	Math based model	Decision Analysis	Decision analysis	Participants used sliders to indicate the importance of competing risks.	Participants were asked to use sliders to indicate the importance of competing risks, such as avoiding death due to flu and avoiding a serious complication such as Guillain-Barre Syndrome from the vaccine. The sliders were constrained such that as a participant moved one slider in one direction, the other automatically moved in the other direction, making the tradeoffs in the decision explicit and salient. We also displayed a recommended option via vertical bars that moved dynamically based on a simple linear function of the slider positions.	1	1	Independently	Parents aged 18+ years who make medical decisions for at least one child aged 6 months to 18 years and whose child had not yet received the flu vaccine.	116	Original survey = 407. Follow-up survey = 116	Standard information (control) vs Standard information +VCM vs Risk communication vs Risk communication +VCM	Randomized: 2 x2 factorial design where the conditions are: (a) Risk Communication (i.e. Standard/Control or Risk Communication presentation of information) and; (b) Values Clarification (i.e. No Values Clarification vs Values Clarification).	Our results suggest that the combination of these two approaches (i.e. present numerical estimates of the risks and benefits of influenza vaccines for children along with values clarification methods intended to help people understand which option is likely to be best aligned with what matters to them) is most effective for encouraging intentions to vaccinate, particularly for parents and guardians who may be more hesitant to vaccinate their children against influenza. Participants randomized to the risk communication condition combined with the values clarification clarification interface were more likely to indicate intentions to vaccinate. The effect was particularly notable among participants who had previously demonstrated less
Witteman 2020 - 2a	Witteman	holly.witteman@fmed.ulaval.ca	2020	What helps people make values-congruent medical decisions? Eleven strategies tested across six studies	5	2	2	Have a colostomy or die	2	Cancer - colon	No specific theory or framework mentioned in article.	After information section on 2 types of surgery to treat colon cancer	Online	Math based model	Decision Analysis	Decision analysis	Strategy 2a: static visual feature explicitly informing participants of the best fit for them.	Strategy 2a: Static visual feature explicitly informing participants of the best fit for them. Both visual features used a box around the choice that aligned with the person's stated values and a saturation fade of 80% on the disgruent choice, thus rendering the values-congruent option as slightly more vivid on the screen.	2	1	Independently	Adults aged 18 years or older living in the United States and able to participate in an English-language online survey.	456	217 in control group and 239 in VCM group	No VCM vs VCM (static visual with information about best choice)	Randomized to receive no intervention (control) or a static visual feature explicitly informing participants of best choice for them.	Providing a recommendation about which option fit best with the participants' stated values before (strategy 2a) or after (strategy 2b) the initial decision increased values congruence.
Witteman 2020 - 2a + 2b	Witteman	holly.witteman@fmed.ulaval.ca	2020	What helps people make values-congruent medical decisions? Eleven strategies tested across six studies	5	2	2	Have a colostomy or die	2	Cancer - colon	No specific theory or framework mentioned in article.	After information section on 2 types of surgery to treat colon cancer	Online	Math based model	Decision Analysis	Decision analysis	Strategy 2a: static visual feature explicitly informing participants of the best fit for them; and 2b: static visual feature providing feedback after their choice if their decision didn't align with their values.	Strategy 2a: Static visual feature explicitly informing participants of the best fit for them. Strategy 2b: Static visual feature providing participants with feedback after their choice if their decision did not align with their values and allowing them to change their choice. Both visual features used a box around the choice that aligned with the person's stated values and a saturation fade of 80% on the disgruent choice, thus rendering the values-congruent option as slightly more vivid on the screen.	2	1	Independently	Adults aged 18 years or older living in the United States and able to participate in an English-language online survey.	456	217 in control group and 102 receiving strategies 2a and 2b	No VCM vs VCM (static visual with information about best choice) and VCM (static visual with information if choice did not align with stated values)	Randomized to receive no intervention (control) or to VCM 2a (static visual with information about best choice) followed by VCM 2b (static visual with feedback after their choice if their decision did not align with stated values).	Providing a recommendation about which option fit best with the participants' stated values before (strategy 2a) or after (strategy 2b) the initial decision increased values congruence.
Witteman 2020 - 4b	Witteman	holly.witteman@fmed.ulaval.ca	2020	What helps people make values-congruent medical decisions? Eleven strategies tested across six studies	5	2	2	Have a colostomy or die	2	Cancer - colon	No specific theory or framework mentioned in article.	After information section on 2 types of surgery to treat colon cancer	Online	Pros and cons	Pros and Cons	Listing	Strategy 4b: prompt to make a deliberative decision + pros and cons writing exercise.	Strategy 4b: Prompt to make a deliberative decision and a deliberative exercise. The specific wording of the prompt was, "On the next few pages, you will be given some information about a medical situation and asked to make a decision about treatment. As you make this decision, try to be rational and intellectual. Make your choice slowly, in a thoughtful way. Use your powers of logic and reason." Participants were then asked to answer 4 groups of questions in small open text boxes: (1) What are the pros of Surgery 1? Which pros are important to you, and why? (2) What are the cons of Surgery 1? Which cons are important to you, and why? (3) What are the pros of Surgery 2? Which pros are important to you, and why? (4) What are the cons of Surgery 2? Which cons are important to you, and why? Strategy 4b is a version of 'pros and cons' values	1	3	Independently	Adults aged 18 years or older living in the United States and able to participate in an English-language online survey.	772	422 in control and 350 receiving strategy 4b	No VCM vs VCM (prompt to make a deliberative decision)	Randomized to receive no intervention or to one or two of eleven strategies - Randomized to receive no intervention (control, n = 422), Strategy 4a (n = 406) or Strategy 4b (n = 350).	Neither encouraging people to make an intuitive decision (Strategy 4a) nor encouraging people to deliberate and providing a deliberation exercise in which they wrote about the pros and cons of each option (Strategy 4b) led to greater values congruence, but the latter led to more people having lower decisional conflict.

Witteman 2020 - 6a	Witteman	holly.witteman@fmed.ulaval.ca	2020	What helps people make values-congruent medical decisions? Eleven strategies tested across six studies	5	2	2	Have a colostomy or die	2	Cancer - colon	No specific theory or framework mentioned in article.	After information section on 2 types of surgery to treat colon cancer	Online	Rating scales	Rating Scales	Rating using sliders	Strategy 6a: nested 2 x 2 factorial design in which the factors are web sliders.	Strategy 6a: Unconstrained dynamic web sliders representing a prototypical values clarification method of rating attributes.	4	3	Independently	Adults aged 18 years or older living in the United States and able to participate in an English-language online survey.	785	422 in control and 363 receiving strategy 6a	No VCM vs VCM (unconstrained dynamic web sliders representing a prototypical values clarification method of rating attributes)	Randomized to receive no intervention or unconstrained dynamic web sliders representing a prototypical values clarification method of rating attributes.	A prototypical 'rating' values clarification method (Strategy 6a) offered no benefit in terms of values congruence compared to the control condition, but did result in reduced decisional conflict. Compared to Strategy 6a, making participants engage with tradeoffs in a decision (Strategy 6b) and showing how options align with stated values (Strategy 6c) resulted in greater values congruence.
Witteman 2020 - 6b	Witteman	holly.witteman@fmed.ulaval.ca	2020	What helps people make values-congruent medical decisions? Eleven strategies tested across six studies	5	2	2	Have a colostomy or die	2	Cancer - colon	No specific theory or framework mentioned in article.	After information section on 2 types of surgery to treat colon cancer	Online	Math based model	Allocation of Points	Allocation of points	Strategy 6b: nested 2 x 2 factorial design in which the factors are web sliders.	Strategy 6b: Dynamic web sliders where the tradeoffs in the decision were made explicit (when the participant moved one slider to the right, the other slider automatically moved the equivalent distance to the left).	1	3	Independently	Adults aged 18 years or older living in the United States and able to participate in an English-language online survey.	817	422 in control and 395 receiving strategy 6b	No VCM vs VCM (constrained dynamic web sliders where tradeoffs in the decision were made explicit)	Randomized to receive no intervention or dynamic web sliders where the tradeoffs in the decision were made explicit.	A prototypical 'rating' values clarification method (Strategy 6a) offered no benefit in terms of values congruence compared to the control condition, but did result in reduced decisional conflict. Compared to Strategy 6a, making participants engage with tradeoffs in a decision (Strategy 6b) and showing how options align with stated values (Strategy 6c) resulted in greater values congruence.
Witteman 2020 - 6c	Witteman	holly.witteman@fmed.ulaval.ca	2020	What helps people make values-congruent medical decisions? Eleven strategies tested across six studies	5	2	2	Have a colostomy or die	2	Cancer - colon	No specific theory or framework mentioned in article.	After information section on 2 types of surgery to treat colon cancer	Online	Math based model	Decision Analysis	Decision analysis	Strategy 6c: nested 2 x 2 factorial design in which the factors are web sliders.	Strategy 6c: Dynamic web sliders explicitly informing participants of the best fit for them (when the participant moved one slider three-quarters of the way to the right the associated vertical bar moved automatically three quarters of the way up).	4	1	Independently	Adults aged 18 years or older living in the United States and able to participate in an English-language online survey.	862	422 in control and 440 receiving strategy 6c	No VCM or VCM (unconstrained dynamic web sliders + explicit implications)	Randomized to receive no intervention or VCM (dynamic web sliders where participants were explicitly informed of the best choice for them).	A prototypical 'rating' values clarification method (Strategy 6a) offered no benefit in terms of values congruence compared to the control condition, but did result in reduced decisional conflict. Compared to Strategy 6a, making participants engage with tradeoffs in a decision (Strategy 6b) and showing how options align with stated values (Strategy 6c) resulted in greater values congruence.
Witteman 2020 - 6b+6c	Witteman	holly.witteman@fmed.ulaval.ca	2020	What helps people make values-congruent medical decisions? Eleven strategies tested across six studies	5	2	2	Have a colostomy or die	2	Cancer - colon	No specific theory or framework mentioned in article.	After information section on 2 types of surgery to treat colon cancer	Online	Math based model	Decision Analysis	Decision analysis	Strategies 6b + 6c: nested 2 x 2 factorial design in which the factors are web sliders.	Strategies 6b and 6c together (i.e. constrained dynamic web sliders and associated vertical bars where when participant moves one slider to the left by one unit the other slider automatically moves to the right by one unit and the associated vertical bars move up and down by one unit respectively).	1	1	Independently	Adults aged 18 years or older living in the United States and able to participate in an English-language online survey.	835	422 in control and 413 receiving strategies 6b + 6c	No VCM vs VCM (constrained dynamic web sliders and associated vertical bars)	Randomized to receive no intervention or VCM (constrained dynamic web sliders and associated vertical bars).	A prototypical 'rating' values clarification method (Strategy 6a) offered no benefit in terms of values congruence compared to the control condition, but did result in reduced decisional conflict. Compared to Strategy 6a, making participants engage with tradeoffs in a decision (Strategy 6b) and showing how options align with stated values (Strategy 6c) resulted in greater values congruence.

Online Appendix 3. Additional Results

Additional Meta-analytic Results

Figure S1. Values Congruence by Tradeoffs



Figure S2. Values Congruence by Implementation/Presentation of Results



Figure S3. Values Congruence by Stated Use of a Theory/Framework



Figure S4. Values Congruence by Real/Hypothetical Decision



Figure S5. Decisional Conflict by Tradeoffs



Figure S6. Decisional Conflict by Implications/Presentation of Results



Figure S7. Decisional Conflict by Stated Use of a Theory/Framework



Figure S8. Decisional Conflict by Real/Hypothetical



Figure S9. Decisional Conflict by Risk of Bias



Head-to-Head Evaluations of Values Clarification Methods

Feldman-Stewart et al. (2006) found no difference across all three groups (information only; values clarification method without a summary bar, i.e. rating scales; values clarification with a summary bar, i.e. multicriteria decision analysis) in terms of the attributes participants identified as important to their decisions nor in how difficult it was to make the decision. When trial participants were unblinded at the end of the study and shown all three options, all of them ranked the bars with the summary option (multicriteria decision analysis) as the most helpful.

Pignone et al. (2012) found that a discrete choice experiment produced somewhat different patterns of attribute importance compared to ranking and rating. Agreement between the most important attribute derived from the values clarification method and the most important attribute as reported by participants in the questionnaire was slightly higher in the ranking and rating arm than the discrete choice experiment arm. The authors found no difference between study arms in terms of values clarity, intent to be screened and unlabelled screening test preference.

Pignone et al. (2013) found that different values clarification methods produced differences in attribute importance and screening test preference. Participants who received the rating and ranking test were more likely to report the chance of dying from prostate cancer as the most important attribute compared to the balance sheet and discrete choice experiment groups. Those who received the balance sheet were more likely to prefer the unlabelled PSA-like test option compared to the two other groups. Participants who received the discrete choice experiment were somewhat less likely to select reduction of mortality as the most important attribute, and were least likely to select the PSA-like option on the unlabelled preference question. There was no difference across groups in intent to be screened (labelled PSA test option) nor on values clarity.

Brenner et al. (2014) found that different values clarification methods produced different results in terms of individuals' most important screening test attributes. Specifically, respondents who received the rating and ranking exercise, compared to a discrete choice experiment or a balance sheet (i.e., implicit values clarification method), were the most likely to choose risk reduction as the most important attribute. They found no differences in terms of test preferences, values clarity, nor intention to be screened.

Witteman et al. (2020) found that overall, methods using mathematical models (e.g., decision analysis, allocation of points) were more promising than other methods (e.g., pros and cons, rating scales) for encouraging values-congruent decisions. All methods encouraged lower decisional conflict when this was assessed.

Risk of Bias

Article	Random Sequence Generation (Selection Bias)	Allocation Concealment (Selection Bias)	Blinding of Participants and Personnel (Performance Bias)	Blinding of Outcome Assessment (Detection Bias)	Incomplete Outcome Data (Attrition Data)	Selective Reporting (Reporting Bias)	Other Bias
Abhyankar 2010	low	unclear	high	unclear	low	low	low
Au 2012	low	low	unclear	unclear	unclear	unclear	unclear
Bekker 2004	low	low	unclear	unclear	unclear	low	low
Brenner 2014	low	low	low	unclear	unclear	low	low
Clancy 1988	low	unclear	unclear	low	unclear	unclear	high
deAchaval 2012	low	low	low	low	low	low	low
Epstein 2018	low	unclear	unclear	high	unclear	low	unclear
Feldman-Stewart 2006	unclear	unclear	unclear	unclear	unclear	unclear	low
Feldman-Stewart 2012	low	low	unclear	low	low	unclear	low
Fraenken 2007	low	low	high	unclear	low	low	low
Frosch 2008	low	low	unclear	low	low	unclear	low
Garvelink 2014 (1)	low	low	low	low	unclear	low	high
Garvelink 2014 (2)	low	low	low	low	low	low	unclear
Hess 2015	low	low	unclear	unclear	unclear	low	unclear
Hopkin 2019	low	low	low	low	unclear	low	unclear
Hutyra 2019	low	unclear	low	low	low	low	unclear
Jayadevappa 2019	low	low	unclear	unclear	low	unclear	unclear
Kennedy 2002	low	low	high	unclear	low	unclear	unclear
Kuppermann 2014	low	low	low	low	low	low	unclear
Lehrman 1997	unclear	unclear	high	unclear	low	low	low
Matheis-Kraft 1997	unclear	unclear	unclear	unclear	low	unclear	unclear
Montgomery 2007	low	low	low	low	low	low	unclear
Montgomery 2003	low	low	high	low	low	unclear	low

Myers 2003	unclear	unclear	unclear	unclear	unclear	low	unclear
Myers 2005	unclear	unclear	unclear	unclear	low	low	unclear
O'Connor 1999	low	low	unclear	low	low	unclear	low
Paquin 2018	low	low	unclear	unclear	low	low	unclear
Peinado 2020	unclear	low	unclear	unclear	unclear	low	low
Pignone 2012	unclear	unclear	low	unclear	unclear	low	low
Pignone 2013	low	low	low	unclear	unclear	low	low
Sheridan 2010	low	low	low	low	low	low	low
Shirk 2017	unclear	unclear	unclear	unclear	low	low	unclear
Witteman 2015	low	low	unclear	unclear	unclear	low	unclear
Witteman 2020	unclear	low	unclear	unclear	low	low	low

Online Appendix 4: PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Title page
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3-5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	na
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6-7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Appendix 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7 - 8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8-9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8-9

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8-9
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10-14
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	14
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	14-17
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	14-17
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Appendix 3
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	14-17
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	17-18
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	18-19
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	19
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	20

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097